

# BMJ Open

## Bridging the Age Gap in Breast Cancer: Evaluation of decision support interventions for older women with operable breast cancer: protocol for a cluster randomised controlled trial.



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015133
Article Type:	Protocol
Date Submitted by the Author:	10-Nov-2016
Complete List of Authors:	<p>Collins, Karen; Sheffield Hallam University, Centre for Health and Social Care Research</p> <p>Lifford, Kate; Cochrane Institute of Primary Care &amp; Public Health, Burton, Maria; Sheffield Hallam University, Centre for Health and Social Care Research</p> <p>Reed, Malcolm; Brighton and Sussex Medical School, Edwards, Adrian; Cardiff University, Division of Population Medicine</p> <p>Ring, Alistair; Royal Marsden NHS Foundation Trust</p> <p>Brain, Kate; Cardiff University, Division of Population Medicine</p> <p>Harder, Helena; University of Sussex, SHORE-C Brighton and Sussex Medical School</p> <p>Robinson, Thomas; University of Leicester, Department of Cardiovascular Sciences</p> <p>Cheung, Kwok; University of Nottingham, School of Medicine</p> <p>Morgan, Jenna; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Audisio, Riccardo; University of Liverpool,</p> <p>Ward, Susan; The University of Sheffield, School of Health and Related Research</p> <p>Paul, Richards; The University of Sheffield, School of Health and Related Research</p> <p>Martin, Charleen; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Chater, Tim; The University of Sheffield, School of Health and Related Research</p> <p>Pemberton, Kirsty; The University of Sheffield, School of Health and Related Research</p> <p>Nettleship, Anthony; The University of Sheffield, School of Health and Related Research</p> <p>Murray, Christopher; The University of Sheffield, School of Health and Related Research</p> <p>Walters, Stephen; University of Sheffield, SCHARR</p> <p>Bortolami, Oscar; The University of Sheffield, School of Health and Related Research</p> <p>Armitage, Fiona; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Robert, Leonard; Imperial College Faculty of Medicine</p> <p>Revell, Deirdre; The University of Sheffield, North Trent Cancer Network Consumer Research Panel</p>

	Gath, Jacqui; Independent Cancer Patients' Voice, Green, Tracy; The University of Sheffield, North Trent Cancer Network Consumer Research Panel Wyld, Lynda; University of Sheffield Medical School, Department of Oncology and Metabolism
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Health services research, Geriatric medicine
Keywords:	CHEMOTHERAPY, Cancer genetics < GENETICS, GERIATRIC MEDICINE, Risk management < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts

1  
2  
3 TITLE: Bridging the Age Gap in Breast Cancer: Evaluation of decision support interventions  
4 for older women with operable breast cancer: protocol for a cluster randomised controlled  
5 trial.  
6  
7

8  
9 Corresponding author:

10 Lynda Wyld,

11 Department of Oncology & Metabolism

12 The Medical School

13 Beech Hill Road

14 Sheffield

15 S10 2RX

16 UK

17 Email: l.wyld@sheffield.ac.uk

18 Tel: +44 (0) 114 2259066  
19  
20  
21

22  
23  
24  
25  
26 Karen Collins, Centre for Health and Social Care Research, Sheffield Hallam University,  
27 Collegiate Crescent, Sheffield, UK.

28  
29 Kate Lifford, Division of Population Medicine, School of Medicine, Cardiff University,  
30 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK

31  
32 Maria Burton, Centre for Health and Social Care Research, Sheffield Hallam University,  
33 Collegiate Crescent, Sheffield, UK.

34  
35 Malcolm Reed, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton,  
36 UK.  
37

38  
39 Adrian Edwards, Division of Population Medicine, School of Medicine, Cardiff University,  
40 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK

41  
42 Alistair Ring, Royal Marsden Hospital, London.

43  
44 Katherine Brain, Division of Population Medicine, School of Medicine, Cardiff University,  
45 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK

46  
47 Helena Harder, SHORE-C, University of Sussex, Falmer, Brighton, UK.

48  
49 Thompson Robinson, Department of Cardiovascular Sciences, Leicester Royal Infirmary,  
50 Infirmary Square, Leicester, LE2 7LX, UK.

51  
52 Kwok Leung Cheung, School of Medicine, University of Nottingham, Royal Derby Hospital  
53 Centre, Uttoxeter Road, Derby DE22 3DT, UK.

54  
55 Jenna Morgan, Department of Oncology and Metabolism, University of Sheffield.  
56  
57  
58  
59  
60

1  
2  
3 Riccardo Audisio, Department of Surgery, University of Liverpool, St Helens Teaching  
4 Hospital, Marshalls Cross Road, St Helens, WA9 3DA, UK.

5  
6 Susan Ward, Department of Health Economics and Decision Science, School for Health and  
7 Related Research, University of Sheffield, Sheffield, UK.

8  
9 Paul Richards, Department of Health Economics and Decision Science, School for Health  
10 and Related Research, University of Sheffield, Sheffield, UK.

11  
12 Charlene Martin, Department of Oncology and Metabolism, University of Sheffield.

13  
14 Tim Chater, Clinical Trials Research Unit, School for Health and Related Research,  
15 University of Sheffield, Sheffield, UK.

16  
17 Kirsty Pemberton, Clinical Trials Research Unit, School for Health and Related Research,  
18 University of Sheffield, Sheffield, UK.

19  
20 Anthony Nettleship, Epigenesys, School for Health and Related Research, University of  
21 Sheffield, Sheffield, UK.

22  
23 Christopher Murray, Epigenesys, School for Health and Related Research, University of  
24 Sheffield, Sheffield, UK.

25  
26 Stephen Walters, Clinical Trials Research Unit, School for Health and Related Research,  
27 University of Sheffield, Sheffield, UK.

28  
29 Oscar Bortolami, Clinical Trials Research Unit, School for Health and Related Research,  
30 University of Sheffield, Sheffield, UK.

31  
32 Fiona Armitage, University of Sheffield, UK

33  
34 Robert Leonard, Imperial College Healthcare NHS Trust, St Mary's Hospital London, UK

35  
36 Jacqui Gath, Deirdre Revell, Tracy Green, Yorkshire and Humberside (formerly North Trent  
37 Cancer Network) Consumer Research Panel.

38  
39 Lynda Wyld, Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.  
40  
41  
42  
43  
44  
45

46  
47 Keywords: Breast cancer, decision aid, elderly, primary endocrine therapy, surgery,  
48 chemotherapy

49  
50  
51 Word count excluding title page, abstract, references, figures and tables: 3885/4000  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

Each year in the UK 16,000 women over the age of 70 develop breast cancer, of whom approximately 6,500 will ultimately die of the disease. Whilst breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable that co-morbidities/frailty rates are higher, which may increase the risks of some breast cancer treatments such as surgery and chemotherapy, many older women are healthy and may benefit from their use. Adjusting treatment regimens appropriately for age/co-morbidity/frailty is variable and largely non-evidence based, specifically with regard to rates of surgery for operable oestrogen receptor (ER) positive disease and rates of chemotherapy for high-risk disease.

### Methods and analysis

This multi-centre, parallel group, pragmatic cluster randomised controlled trial (2015-18), nested within a larger ongoing “Age Gap Cohort Study” (2012-18; RP-PG-1209-10071), aims to evaluate the effectiveness of a complex intervention of decision support interventions (DESI) to assist in the treatment decision-making for early breast cancer in older women. The interventions include two patient decision aids (PtDAs) (primary endocrine therapy versus surgery/AET and chemotherapy versus no chemotherapy) and a clinical treatment outcomes algorithm for clinicians.

The primary outcome will be quality of life measured by EORTC QLQ C30. Secondary outcomes will include decision quality, coping, decision regret and treatment allocations

1  
2  
3 Randomisation is at breast unit level, stratified by high/ low primary endocrine therapy and  
4 chemotherapy rates. Women (n=1500) over 70 years with primary operable breast cancer will  
5 be recruited and followed up 6 weeks to 2 years post diagnosis with longer term cancer  
6 outcomes (overall survival, disease free survival) derived from cancer registry returns.  
7  
8 Control arm: no change to usual practice. Intervention arm: usual practice plus DESIs  
9  
10 adopted as standard care by clinicians.  
11  
12  
13  
14  
15  
16

17 **Ethics:** London South East NHS Research Ethics Committee 12/LO/1808  
18  
19

20 IRAS reference 115550  
21  
22

23 **Trial registration detail/number:**  
24

25  
26 European Union Drug Regulating Authorities Clinical Trials (EudraCT) number 2015-  
27 004220-61  
28

29 Sponsor's Protocol Code Number Sheffield Teaching Hospitals STH17086  
30

31 ISRCTN 32447  
32  
33  
34  
35  
36

37 **Strengths and limitations of this study**  
38

- 39  
40 1. This study has developed two evidence based decision support interventions (DESI)  
41 for women over 70 years diagnosed with breast cancer who are offered a choice of  
42 primary endocrine therapy (PET) or surgery (plus adjuvant endocrine therapy,  
43 hereafter termed surgery/AET) or chemotherapy versus no chemotherapy.  
44  
45  
46  
47  
48 2. A model of outcomes for older women treated by either PET or surgery/AET or by  
49 chemotherapy versus no chemotherapy. These data have been used to construct a web  
50 based clinical outcomes management algorithm which allows patient age, co-  
51 morbidities, frailty and cancer characteristics to be considered in predicting survival  
52 and cancer outcomes.  
53  
54  
55  
56  
57  
58  
59  
60

3. This study will determine the effectiveness of the implementation of the two DESIs on health care outcomes (quality of life, decision quality, coping, decision regret, treatment allocations and short/medium/longer term oncology outcomes).
4. Limitations of the study will potentially be selection bias from recruitment and poor uptake/utilisation of the DESIs at intervention sites, inability to demonstrate a benefit in terms of cancer survival rates without at least 5-10 years follow up or an overall survival advantage due to the competing causes of death in this age group.

## INTRODUCTION

### Background and rationale

Breast cancer is the most common cancer in women in the UK, with over 53,000 new cases being diagnosed in the UK each year [1]. Of these, 16,000 women will be over the age of 70, a figure which is rising steadily as the UK population ages [2]. Whilst breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes in this older age group of women. The UK lags significantly behind other European countries in its outcomes for these women. There is a wide variation in practice in the management of breast cancer in older women [3]. The gold standard of care for early breast cancer is surgical removal of the primary cancer (mastectomy or conservation surgery), and diagnostic or therapeutic axillary nodal surgery followed by stage and immunophenotype appropriate adjuvant therapies (chemotherapy, trastuzumab, anti-oestrogens and radiotherapy) to reduce the risks of disease recurrence. There is consistent evidence that older women are less likely to receive surgery, chemotherapy, radiotherapy and trastuzumab, based on the premise that there is less evidence of efficacy and a greater risk of treatment morbidity [4]. In the case of surgery, up to 40% of

1  
2  
3 older women do not undergo surgery for their breast cancer, and their treatment is mainly with  
4 anti-oestrogen tablets alone, known as primary endocrine therapy (PET) [5]. Whilst it is  
5 inevitable that in older women, co-morbidities and frailty rates are higher, and which will  
6 increase the risks of some breast cancer treatments, such as surgery and chemotherapy, many  
7 older women are healthy and will benefit in terms of breast cancer outcomes, from their use.  
8 Selection of appropriate age, co-morbidity and frailty adjusted treatment regimens is highly  
9 variable, largely non-evidence based, and often fails to adequately consider the needs or  
10 wishes of patients. Two key areas of local practice variation are rates of surgery for operable  
11 oestrogen receptor (ER) positive disease and rates of chemotherapy for high risk disease. PET  
12 rates vary four fold between UK centres [3] and are not accounted for by case mix adjustment.  
13 Similarly rates of chemotherapy vary 10-fold [4].

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 Recent reports have advocated the use of PET only in the very old or frail [6]. Current  
29 national guidelines state that patients with operable breast cancer should be treated with  
30 surgery, and not PET, “irrespective of age” unless this is precluded by co-morbidities [7];  
31 whilst the International Society of Geriatric Oncology (SIOG) and European Society of  
32 Breast Cancer Specialists (EUSOMA) recommend that PET should only be offered to  
33 patients with a “short estimated life expectancy (less than 2 to 3 years), who are considered  
34 unfit for surgery... or who refuse surgery” [8]. However, as a large number of older women  
35 are treated with PET in UK and other countries, it is not clear whether this guidance is being  
36 followed consistently. PET is associated with high rates of patient satisfaction and low  
37 treatment morbidity but in the medium and long term some women may need a change of  
38 therapy once anti-oestrogen resistance develops [9]. Randomised trials and a recent Cochrane  
39 review have shown that surgery (plus adjuvant anti-oestrogens herein after termed  
40 surgery/AET) and PET have equivalent overall survival rates [10-11], although local control  
41 rates are superior in surgically treated patients, with disease progression sometimes  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 necessitating a change of management in patients treated with PET [13-15]. However, for  
4  
5 fitter women with a longer predicted life expectancy, there is evidence that breast cancer  
6  
7 specific survival rates are inferior with PET [12]. For very frail women where surgery would  
8  
9 be unsafe or poorly tolerated, PET is the clear choice in women with oestrogen sensitive  
10  
11 disease.  
12

13  
14 For women at intermediate or higher risk of surgery there is a complex series of trade-offs to  
15  
16 be made for each patient. The decision must balance the risks of surgical morbidity (pain,  
17  
18 risks associated with hospitalisation, surgical complications) but with a greater certainty of  
19  
20 local disease control, against the minimal morbidity with PET but a risk of later local disease  
21  
22 progression and the need for a change of treatment to either surgery or alternate anti-  
23  
24 oestrogen therapy[13-15].  
25  
26

27  
28 Chemotherapy utilisation is also very low in women over 70 (14%) [4] and almost non-  
29  
30 existent in women over 80, even in those where high phenotypic risk is present (high grade,  
31  
32 node positive, ER negative, her-2 positive) [4]. This reflects the fact that whilst there is  
33  
34 ample evidence of benefit for chemotherapy in women under 70, most of the randomised  
35  
36 trials have upper age cut offs at age 70 or recruit very poorly in this age group, meaning there  
37  
38 is little evidence of whether it is effective or not. In addition, there is evidence of an increased  
39  
40 risk of significant complications such as neutropenic sepsis in older women [17]. Rates of  
41  
42 chemotherapy vary widely between UK breast units, between 6 and 60% in high risk women  
43  
44 [16]. This clearly suggests that guidelines for best practice are required. The primary tool  
45  
46 used by oncologists to determine the likely benefit of chemotherapy on a patient level basis is  
47  
48 Adjuvant! Online [18], although this has been shown to be inaccurate in older women [19].  
49  
50 The more recently developed PREDICT tool [20] performs better in this age group but has  
51  
52 limited functionality for taking co-morbidity and frailty into account.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This cluster randomised trial will evaluate the implementation of two (“complex”) decision  
4 support interventions (DESI) designed to be used by both clinicians and patients to assist in  
5 the decision making about treatment for early breast cancer in older women.  
6  
7  
8  
9

### 10 **The Age Gap Study**

11  
12  
13 The Bridging the Age Gap study [21] is a NIHR funded programme of research (2012-18RP-  
14 PG-1209-10071) examining breast cancer management in older women with the ultimate aim  
15 of improving outcomes by providing high quality evidence to support treatment decision  
16 making in this age group. Two clinical decisions are being studied: the decision relating to  
17 the choice of surgery/AET or PET in frailer women with ER positive breast cancer, and the  
18 decision regarding use of adjuvant chemotherapy in fitter women with high risk cancers. The  
19 study group has developed two decision support interventions (DESI) based on a systematic  
20 evidence summary, expert reference group consultation, patient interviews [22-24] and  
21 questionnaires about informational needs and preferences and extensive user- and field-  
22 testing with both healthy older women and older women who had faced these decisions. Each  
23 DESI includes a clinical management algorithm and two patient decision aids (PtDAs) in the  
24 form of a booklet [26, 27] and a (brief) option grid for the clinical decision in question. The  
25 clinical management algorithms derive from detailed cancer registry outcome data linked to  
26 treatment related morbidity and patient and cancer characteristics from the UK cancer  
27 registry (2002-2010) for two UK regions (Northern and Yorkshire and East Midlands) [25].  
28 These online algorithms allow patient age, co-morbidities, frailty and cancer characteristics to  
29 be considered by a clinician in predicting survival and cancer outcomes and to help inform  
30 breast cancer management decisions for older women [25].  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54 The trial will evaluate these tools in a cluster randomised trial across 46 UK breast units  
55 according to the study schematic (Figure 1).  
56  
57  
58  
59  
60

1  
2  
3 The aims of this study are to evaluate if, how and to what extent, the use of the DESIs  
4 embedded as ‘standard of care’ within intervention-arm sites, improves QoL, decision quality  
5 (integrating knowledge, attitudes and decision made), coping, illness representations and  
6 reduces decision regret, thus indicating improved informed decision making of older women  
7 about treatment options for their breast cancer.  
8  
9

10  
11  
12 To our knowledge this is the first randomised controlled trial to have been undertaken to  
13 explore this issue.  
14  
15  
16  
17  
18  
19

## 20 **Objectives**

21 The objectives are to:

- 22  
23  
24  
25  
26  
27 1. To assess the effectiveness of the implementation of DESIs [26][27] in clinical  
28 practice in terms of improving patient QoL, decision quality (integrating knowledge,  
29 attitudes and decision made), coping, illness representations and reducing decision  
30 regret, thus indicating improved informed decision making.  
31  
32  
33  
34  
35
- 36  
37 2. To determine if, how, or to what extent, the clinical outcomes management algorithm  
38 impacts on clinical decision making among clinicians (change in PET/surgery rates  
39 and chemotherapy rates).  
40  
41  
42
- 43  
44 3. To determine whether the DESIs are effective in improving short, medium and long  
45 term cancer outcomes in this age group of women, (treatment morbidity and overall  
46 and disease specific survival).  
47  
48
- 49  
50 4. To assess the utility and uptake of the DESIs from the perspective of both clinicians  
51 and patients by undertaking a formal process evaluation.  
52  
53  
54

## 55 **Hypotheses**

56  
57  
58  
59  
60

- 1  
2  
3 1. Use of the DESIs will improve the quality of life in older women with operable  
4 breast cancer and ultimately improve cancer outcomes.  
5  
6
- 7 2. Older women faced with a choice of treatment decisions for their breast cancer will  
8 report an improved decision quality and shared decision-making experience and less  
9 decision regret using DESIs compared to older women who receive usual clinical  
10 decision making support.  
11  
12
- 13 3. Use of evidence based DESIs will improve short and longer term outcomes by  
14 improving treatment personalisation to a woman's health, fitness and cancer  
15 characteristics and by improving the quality of decision making, reduce the  
16 heterogeneity of practice across the UK.  
17  
18
- 19 4. Women in the intervention sites will express more positive illness representations (e.g.  
20 increased personal control, positive emotional consequences, less overall threat) and  
21 increased use of engagement coping strategies compared to women from the control  
22 sites.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36


## 37 **METHOD**

### 38 **Study design and setting**

39  
40  
41  
42  
43  
44 This protocol follows the CONSORT statement guidelines for cluster trials [28].  
45  
46

47 This study is a multi-centre, parallel group, pragmatic cluster randomised controlled trial  
48 (2015-18) [29]. It is nested within a larger ongoing Age Gap Cohort Study (2012-18)  
49 [21](Figure 1) which is currently recruiting from 46 breast units within in the UK  
50 (observational cohort study of current UK management of older women with early breast  
51 cancer).  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: Age Gap study



## Eligibility criteria

### Inclusion criteria

- (1) Female
- (2) Aged over 70 years of age at the time of diagnosis of cancer
- (3) Primary operable (TNM categories V7: T1, T2, T3, N0, N1, M0), ER positive invasive breast cancer (core biopsy or diagnostic incision biopsy)
- (4) Ability to give informed consent and to read English

### Exclusion criteria

- (1) Disease unsuitable for surgery e.g. inoperable, locally recurrent or metastatic disease.
- (2) Previous invasive breast cancer within the last 5 years.
- (3) Non-English speakers

## The RCT study

The intervention comprises implementation of a package of two DESIs for the PET versus surgery/AET, or chemotherapy versus no chemotherapy decisions. Each DESI includes an online algorithm for treatment outcomes, and two patient decision aids (PtDAs)– a booklet and a brief option grid [26-27]. Each DESI is a complex intervention, including training for the clinician in shared decision making and use of the algorithm or PtDAs, and the clinician and patient decide which, if any, of these elements they wish to use to assist the decision making process.

Each online algorithm includes functionality to adjust outcome prediction according to patient age, co-morbidity, frailty, tumour stage and ER status and which gives outputs of 2 and 5 year overall and breast cancer specific survival (Figure 2, illustrating online decision aid outputs).




Figure 2. Screen shots from the on line algorithm giving examples of outputs from the tool. A. A fit 70 year old woman with a large node positive ER negative cancer showing the 5 year survival difference of having adjuvant chemotherapy. B, a very frail 93 year old with dementia, cardiac failure and significant dependency showing the relative risks of surgery or PET and C, a moderately fit 82 year old with a strongly ER positive tumour showing the relative risks at 2 years of PET versus surgery.

1  
2  
3 The algorithms were developed in the earlier phase of the Age Gap Study [25] and  
4  
5 weredesigned to guide clinicians and their patients in the treatment of:  
6  
7

8 (1) frailer older women with ER positive breast cancer to optimise treatment with either PET  
9  
10 or surgery/AET,  
11


12  
13 or  
14

15  
16 (2) fitter older women who have already had primary surgery and been found to have high  
17  
18 risk cancer characteristics (e.g. ER negative, Her 2 positive or node positive breast cancer) to  
19  
20 optimise treatment with either adjuvant chemotherapy or no adjuvant chemotherapy (note the  
21  
22 term chemotherapy includes chemotherapy +/- trastuzumab if appropriate).  
23  
24

25  
26 The algorithm is based on a computer model of predicted outcomes and variance caused by  
27  
28 patient and disease parameters. Unlike existing web based algorithms for cancer treatment  
29  
30 (Adjuvant! OnLine [19] or PREDICT [20]) which do not have the facility to specify frailty or  
31  
32 comorbidity in detail (or at all), the Age Gap algorithm permits these factors to be taken into  
33  
34 account. The Age Gap tool has been optimised for accuracy in this age group and has been  
35  
36 based on analysis of data from over 20 000 UK women over the age of 70 derived from  
37  
38 cancer registry data. The algorithm has built in educational materials (including several on  
39  
40 line presentations, data sources, FAQs and an animated educational video). The online  
41  
42 algorithm is designed to be used by clinicians to guide treatment decision making and also for  
43  
44 its outputs to be printed off in a patient facing format that could be used in personalised  
45  
46 patient counselling. The report that can be printed off gives specific survival estimates for  
47  
48 each treatment option for an individual woman based on her personal and cancer  
49  
50 characteristics. This works in much the same way as the print outs from Adjuvant! Online  
51  
52 [19] or PREDICT [20] but in this case developed for the PET versus surgery/AET decision  
53  
54 and with more detailed data entry relating to the woman's age and fitness level.  
55  
56  
57  
58  
59  
60

Two PtDAs (PET versus surgery/AET [26] and chemotherapy versus no chemotherapy [27]) have been developed during the earlier phase of the study [22-24]. The PtDAs comprise of an option grid [30] and a booklet for each decision (figure 3). The option grid is a one page evidence-based summary of the treatment options alongside patients' frequently asked questions, helping patients to differentiate the key features, risks and benefits of treatment options in relation to their personal values and preferences. The option grid has been designed to be sufficiently brief for use in clinical encounters and accessible enough to support a better dialogue between patients and their clinical team [30]. The booklet provides information about both options including diagrams, side effects and potential risks and benefits. It also includes a section to guide deliberation and encourage the patient to clarify their preferences based around identifying "what is most important to them" [16].

Figure 3. The two patient decision aid booklets for decision support for women facing a PET versus surgery/AET decision [26] or chemotherapy versus no chemotherapy [27] decision.





## Data Collection and Outcomes.

### Primary outcome measure

The primary outcome measure is global health status/QoL score (questions 29+30 only of The European Organization for Research and Treatment of Cancer QLQ-C30 Reference Manual) (EORTC QLQ-C30) [31] at 6 weeks and 6 months post diagnosis/consent.

Data collection for the study includes detailed information about the patient and their cancer at the time of diagnosis: age, comorbidity (Charlson co-morbidity index [32], frailty- The Barthel Index (ADL) [33] and instrumental activities of daily living scores (IADL) [34]), cognitive status (Mini-mental state examination-MMSE) [35], baseline QoL (EORTC QLQ C30 [31], EORTC breast cancer-specific QoL questionnaire (QLQ-BR23) [36], EORTC QoL questionnaire module for older people with cancer (QLQ-ELD14) [37], EuroQol Group EQ-5D [38]), tumour stage, grade and receptor status. Treatment details are recorded including the type of surgery to the breast and axilla, use of adjuvant therapies (chemotherapy, radiotherapy, trastuzumab and hormonal therapies), including doses and adverse effects recorded using the Common Terminology Criteria for Adverse Events grading system. Follow up is at baseline, 6 weeks, 6, 12, 18 and 24 months after diagnosis/consent. Cancer outcomes, QoL and adverse events are recorded at each visit and in the longer term, women are asked to sign a consent form to permit the trial to collect their Cancer Registry data which will be collected 5 and 10 years following diagnosis and consent to the study. These data will permit us to look at whether using the DESIs alters patterns of treatment decision making between control and intervention sites and whether these impact on long term outcomes. As such this is a uniquely detailed evaluation of such DESIs.

1  
2  
3 In addition, specific questionnaires relating to patient choice and decision making will be  
4 administered. These will apply to all women offered a choice of either PET and surgery/AET  
5 or chemotherapy versus no chemotherapy and are administered in relation to the time of their  
6 treatment choice.. Secondary outcomes measures here include decision regret (Decision  
7 Regret Scale [39], shared decision making (CollaboRATE [40]), patient anxiety (Spielberger  
8 short-form State scale of the State-Trait Anxiety Inventory [41], knowledge and preference  
9 (knowledge,readiness to decide and preference measure [42-43]), illness perceptions (Brief  
10 Illness PerceptionsQuestionnaire [44]) and Coping(brief COPE)[45]).  
11  
12  
13  
14  
15  
16  
17  
18  
19

20  
21  
22 The timescales for each of these are shown in Table 1.

23  
24 Table 1.Data items relating to patient-based outcomes and cancer characteristics.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: Questionnaire Schedule**

Standard Age Gap Questionnaires	Baseline	6 weeks	6mths	12mths	18/24 mths	Long-term
IADL	*					
ADL	*					
MMSE	*					
ECOG perf. status	*					
Subjective Global Assessment	*					
Co-morbidity	*					
EQ5D	*	*	*	*	*	
QoL (EORTC-QLQ C30; QLQ-BR23 and (QLQ-ELD14))	*	*	*	*	*	
Decision quality	*	*				
RECIST if PET	*	*	*	*	*	
Registry data access						*
Tissue Access	*					*
Tumour details	*					
Treatment details	*	*	*	*	*	
Adverse events	*	*	*	*	*	
<b>New for DESI study</b> (if offered choice of either PET or surgery/AET, or chemotherapy/no chemotherapy)	Baseline (after consent for PET or surgery (AET or after consultation for chemo/no chemo, as applicable)	6 weeks after relevant treatment choice	6 months after relevant treatment choice			
Spielberger Anxiety		*	*			
Collaborate	*					
Decision Regret		*	*			
Knowledgereadiness to decide and preference measures	*					
Brief IPQ		*	*			
Brief COPE		*	*			
<b>Process evaluation</b> (if taking part in process evaluation)						
Process evaluation questionnaire		*				

### Sample size calculation

The primary endpoint will be the global health status/QoL score (questions 29+30 of EORTC QLQ-C30 [31]) at 6 weeks and 6 months post-diagnosis/consent intervention. Assuming 46 units are randomised to either the DESI interventions (25 units) or control (normal care- 25 units) then we can estimate a preliminary sample size assuming a fixed number of clusters ( $k=46$ ) and attempt to recruit a set number of women per cluster (38). Data from the EORTC Reference Manual [46] suggests a mean Global health status/QoL score of 58.2 with a SD of 25.6 for women aged 70 or more with breast cancer. Cocks and colleagues [47] (suggested the following guidelines for interpreting the Global health status/QoL with estimates for trivial, small, and medium mean differences of 1, 7, and 13 points respectively.

With a standard deviation of 26 points for the Global Health Status/QOL scale we will assume that a mean difference of 7 or more points in Global Health Status/QOL scores between the groups is of clinical/practical importance (a “small” standardised effect size of 0.27). With no allowance for clustering; for the PET versus surgery/AET DESI comparison with 291 eligible women per group we will have 90% power of detecting this difference or more as statistically significant between the groups at the 5% two-sided level. If we assume an intra-class correlation of 0.05 then allowing for the clustered RCT design we will need to recruit 25 women, eligible for the using the decision aids, per cluster (i.e. 50 clusters x 25 women), 1250 in total (this assumes a design effect of 2.2). With a 20% loss to follow-up by six months we need to recruit 34 women per cluster (48 clusters x 32) or 1500 in total (750 per group). Based on our site recruitment data the majority of sites will achieve this number of cases after being open for 24 months.

### Randomisation

1  
2  
3 Randomisation is at breast unit level, stratified by high and low PET and chemotherapy rates.  
4  
5 Data for this stratification have been derived from the wider cohort study which has collected  
6  
7 data on treatment rates for both PET versus surgery/AET and chemotherapy versus no  
8  
9 chemotherapy.  
10

11  
12 **Control arm.** Usual standard practice for older women (>70 years) diagnosed with breast  
13  
14 cancer with no change to normal treatment decision making practice.  
15  
16

17  
18 **Intervention arm.** Usual standard practice for older women (>70 years) diagnosed with  
19  
20 breast cancer plus optional clinician and patient access to the package of DESIs which will  
21  
22 have been made available to these units to adopt as their standard of care.  
23  
24

25  
26  
27 In the run in to the trial period (June–Dec 2015), clinical teams (clinicians, research and  
28  
29 breast nurses) from the participating sites attended a training event to enhance concordance  
30  
31 with the study protocol (control group) and provide additional training on shared decision  
32  
33 making and the use of the DESIs (intervention group). This comprised of a 2 hour practical  
34  
35 workshop which consisted of presentations, demonstrations and discussion based on the  
36  
37 MAGIC programme [50].  
38  
39

#### 40 41 **Recruitment** 42

43  
44  
45  
46 Potentially eligible women are identified by clinicians and research nursing staff within multi  
47  
48 disciplinary teams of the study sites. Study packs are being given to eligible patients either  
49  
50 following their clinical consultation where either PET or surgery/AET options or  
51  
52 chemotherapy versus no chemotherapy options are discussed.  
53  
54  
55  
56  
57  
58  
59  
60

### Data analysis

The statistical analyses will be performed on an intention-to-treat basis comparing the DESI and control groups. All statistical exploratory tests will be two-tailed with  $p=0.05$ . Baseline demographic (e.g. age), physical measurements, and health-related QoL data will be assessed for comparability between the treatment groups. A marginal Generalised Linear Model (GLM), with coefficients estimated using generalised estimating equations (GEE) with robust standard errors and an exchangeable auto correlation matrix in STATA v13 [48-49] will be used to analyse the outcomes and allow for the clustered nature of the data. The exchangeable correlation structure corresponds to an equal correlation model, meaning that the correlations of the outcomes with a cluster, i.e. breast centres, are the same.

1  
2  
3 For continuous outcomes, such as mean global health status/QoL score (questions 29+30 of  
4 EORTC QLQ-C30 [31]) at 6 months post-diagnosis/consent intervention, knowledge score  
5 and preference for treatment score, an identity link with a Normal distribution for the  
6 outcome will be used. Estimates for the treatment group coefficient from this regression  
7 model will be reported along with their associated 95% confidence interval. In the event of  
8 differences between the intervention and control groups with respect to baseline demographic,  
9 physical, and health-related QoL measurements, then these covariates will be used in the  
10 GLM to adjust the treatment effect for these variables. The adjusted regression coefficient  
11 estimate for the treatment group parameter along with its 95% confidence interval (CI) will  
12 then be reported.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25  
26 For the other secondary outcomes, at 6 weeks and 6 months, such as the other dimensions of  
27 the EORTC QLQ C30 [31], the EORTC QLQ-BR23 [36] and EORTC QLQ-ELD14 [37] the  
28 mean QoL dimension scores will be compared between the intervention and control groups,  
29 using similar models.  
30  
31  
32  
33  
34

35  
36 A series of exploratory sub group analyses using a marginal GLM with coefficients estimated  
37 using GEE with robust standard errors and an exchangeable auto correlation matrix, with the  
38 primary outcome the mean Global health status/QoL score (questions 29+30 of EORTC  
39 QLQ-C30 [31]) at 6-month post-diagnosis/consent randomisation as the response will be  
40 carried out. An interaction statistical test between the randomised intervention group and  
41 subgroup to directly examine the strength of evidence for the treatment difference between  
42 the treatment groups (Intervention versus Control) varying between subgroups will be  
43 undertaken. Age subgroup (75-79, 80-84, 85-89 and 90+ years) and co-morbidity levels  
44 (based on the modified Charlson co-morbidity score [32]) will be the only a priori defined  
45 sub groups to be considered for interaction test. Sub group analysis will be performed  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 regardless of the statistical significance on the overall intervention effect (intervention versus  
4  
5 control).  
6  
7

#### 8 Missing primary outcome data 9

10  
11 A sensitivity analysis using a variety of imputation methods, to impute any missing primary  
12  
13 outcome data (6-month EORTC QLQ-C30 [31] global health status/QoL score) will be  
14  
15 performed. The imputation methods will include last observation carried forward, regression  
16  
17 and multiple imputation. The estimates of the treatment effect and its associated confidence  
18  
19 interval, from the various imputation methods, will be graphically displayed alongside the  
20  
21 results for the observed data.  
22  
23  
24

#### 25 **Process Evaluation** 26

27  
28  
29 Running alongside the main study, a detailed mixed methods process evaluation is being  
30  
31 undertaken at 16 sites to assess the implementation of the DESIs (fidelity to the trial protocol)  
32  
33 to consider the DESIs' usefulness and acceptability and examine the facilitators and barriers  
34  
35 to embedding them into everyday clinical practice. A random selection of breast units was  
36  
37 made stratified by trial arm and recruitment rate to the cohort study (high/low  
38  
39 PET/surgery/chemo rates).  
40  
41  
42

43  
44 In summary, the Age Gap study [21] aims to improving outcomes of older women diagnosed  
45  
46 with breast cancer by providing high quality evidence to support treatment decision making  
47  
48 in this age group. The two evidence based DESIs each include a clinical management  
49  
50 algorithm and two patient decision aids (PtDAs) in the form of a booklet and a (brief) option  
51  
52 grid for the clinical decision in question. These online algorithms will allow patient age, co-  
53  
54 morbidities, frailty and cancer characteristics to be considered by a clinician in predicting  
55  
56  
57  
58  
59  
60



1  
2  
3 survival and cancer outcomes and to help inform breast cancer management decisions for  
4  
5 older women.  
6  
7

## 8 9 **ETHICS AND DISSEMINATION**

10  
11 The study has been fully ethically approved and R and D approval gained at all UK sites.  
12  
13

### 14 15 16 **Acknowledgments**

17  
18 The authors are grateful to all participating sites, and specifically site principal investigators  
19  
20 (PI) who have or who are currently contributing to the RCT.  
21  
22  
23

24  
25 **Competing interests:** None declared  
26  
27

28 **Funding:** This work is supported by National Institute of Health Research Programme Grant  
29  
30 [grant number RP-PG-1209-10071]  
31  
32

33 **Contributors** LW, KC and MR were overall project leads. Decision aid development and  
34  
35 testing KL, MB, KC, LW, MR, AE, KB, JG, DR, FA, HH. Trial management: LW, CM, TC,  
36  
37 KP. On line tool development: LW, SW, PR, AN, CM, MB, JM. Statistical advice: SW, OB.  
38  
39 Trial management group: LW, MR, KC, TR, KLC, AR, etc. Chemotherapy advisors: AR,  
40  
41 RL, HH. All authors have contributed to reading and approved the final manuscript.  
42  
43

44  
45 **Provenance and peer review:** Not commissioned; externally peer reviewed  
46  
47

48 **Open access:** This is an Open Access article distributed in accordance with the Creative  
49  
50 Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to  
51  
52 distribute, remix, adapt, build upon this work non-commercially, and license their derivative  
53  
54 works on different terms, provided the original work is properly cited and the use is non-  
55  
56 commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>  
57  
58  
59  
60

## REFERENCES

1. Cancer Research UK breast cancer incidence [accessed 1/11/2016] Available from <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer>
2. Office for National Statistics. New cases of cancer diagnosed in England, 2014: selected sites by age group and sex. Office for National Statistics 2010[accessed 1/11/2016] Available from <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregistrationssummarytables/previousReleases>
3. Morgan J, Richards P, Ward S et al (2015) Case mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer. *British Journal of Surgery*. 102 (9), 1056-1063.
4. Ring A, Harder H, Langridge C et al. Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. *Ann Oncol*. 2013;24(5):1211-9.
5. BCCOM. Breast Cancer Clinical Outcome Measures (BCCOM) Project. Birmingham, UK; 2007
6. Chakrabarti J, Kenny FS, Syed BM, et al. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer- final results at 20-year follow-up. *Crit Rev Oncol Hematol* 2011;78:260-264.
7. NICE. Early and locally advanced breast cancer: full guideline. Cardiff: National Collaborating Centre for Cancer; 2009.
8. Biganzoli L, Wildiers H, Oakman C. et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology

- 1  
2  
3 (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). *Lancet Oncol*  
4  
5 2012;13:e148-e160.  
6  
7  
8 9. Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older  
9  
10 women with operable breast cancer - a comparison of randomised controlled trial and  
11  
12 cohort study findings. *Eur J Surg Oncol*. 2014;40(6):676-84.  
13  
14  
15 10. Glas de, NA, Jonker JM, Bastiaannet E, et al. Impact of omission of surgery on  
16  
17 survival of older patients with breast cancer. *Br J Surg*. 2014;101(11):1397-404.  
18  
19  
20 11. Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone  
21  
22 for older women with operable breast cancer: cochrane review. *Br J Cancer*.  
23  
24 2007;96(7):1025-9.  
25  
26  
27 12. Morgan J, Wyld L, Collins K, et al. Surgery versus primary endocrine therapy for  
28  
29 operable primary breast cancer in elderlywomen (70 years plus). *Cochrane Db Syst*  
30  
31 *Rev* 2014;5: CD004272.  
32  
33  
34 13. Audisio RA, Wyld L. No standard is set for older women with breast cancer. *Eur J*  
35  
36 *Surg Oncol* 2015 May; 41 (5): 607  
37  
38  
39 14. Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older  
40  
41 women with operable breast cancer - a comparison of randomised controlled trial and  
42  
43 cohort study findings. *Eur J Surg Oncol*. 2014;40(6):676-84.  
44  
45  
46 15. Hille U, Soergel P, Länger F, et al. Aromatase inhibitors as solely treatment in  
47  
48 postmenopausal breast cancer patients. *Breast J* 2012; 18(2):145–50.  
49  
50  
51 16. Elwyn G, Frosch D, Thomson R et al. Shared decision making: a model for clinical  
52  
53 practice. *J Gen Intern Med* 2012 Oct; 27 (10): 1361-7.  
54  
55  
56 17. NICE Clinical guideline. Neutropenic sepsis: prevention and management in people  
57  
58 with cancer. CG151]Published date: September 2012  
59  
60

- 1  
2  
3 18. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making  
4 decisions about adjuvant therapy for women with early breast cancer. *J Clin Oncol.*  
5 2001;19(4):980-91.  
6  
7  
8  
9  
10 19. deGlas NA, van de Water W, Engelhardt EG, et al. Validity of Adjuvant! Online  
11 program in older patients with breast cancer: a population-based study. *Lancet Oncol.*  
12 2014;15(7):722-9.  
13  
14  
15  
16 20. Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic  
17 model that predicts survival following surgery for invasive breast cancer. *Breast*  
18 *Cancer Res.* 2010; 12(1): R1. Published online 2010 January 6. doi: 10.1186/bcr2464.  
19  
20  
21  
22  
23  
24  
25  
26 21. Wyld L, Reed MWR, Collins K et al .Bridging the Age Gap in Breast Cancer:  
27 Improving outcomes for older women NIHR Programme grant 2012-17RP-PG-1209-  
28 10071[Accessed 18/11/ 2016] Available at [http://www.nihr.ac.uk/funding/funded-](http://www.nihr.ac.uk/funding/funded-research/funded-research.htm?postid=2237)  
29  
30  
31  
32  
33  
34 22. Lifford KJ, Witt J, Burton M, et al. Understanding older women's decision making  
35 and coping in the context of breast cancer treatment. *BMC Medical Informatics &*  
36  
37  
38  
39  
40  
41 23. Burton M, Collins K, Caldon LJM et al. Information Needs of Older Women Faced  
42 With a Choice of Primary Endocrine Therapy or Surgery for Early Stage Breast  
43  
44  
45  
46  
47  
48 24. Burton M, Collins K, Lifford K et al. The information and decision support needs of  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 25. Richards P, Ward S, Morgan J, et al. The use of surgery in the treatment of ER+ early  
4 stage breast cancer in England: variation by time, age and patient characteristics.  
5 European Journal of Surgical Oncology. 2016; 42(4) 489-96.  
6  
7  
8  
9  
10 26. Deciding about your breast cancer treatment: surgery and hormone-blocking pills or  
11 hormone-blocking pills only. Cardiff University, The University of Sheffield,  
12 Sheffield Hallam University developed as part of the Bridging the Age Gap Study  
13 (RP-PG-1209-10071) August 2015.  
14  
15  
16  
17  
18 27. Deciding about your breast cancer treatment: chemotherapy or no chemotherapy. The  
19 University of Sheffield ,Brighton and Sussex Medical School, Sheffield Hallam  
20 University and Cardiff Universityas part of the Bridging the Age Gap Study (RP-  
21 PG-1209-10071) January 2016.  
22  
23  
24  
25  
26  
27 28. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated  
28 guidelines for reporting parallel group randomized trials. Ann Intern Med.  
29 2010;152(11):726-32.  
30  
31  
32  
33  
34 29. Wyld L, Reed MWR, Collins K on behalf of the Age Gap study. A multi-centre, parallel  
35 group, pragmatic cluster randomised controlled trial NIHR Programme grant RP-PG-1209-  
36 1007.EUDRACT No:2015-004220-61  
37  
38  
39  
40  
41  
42 30. Marrin k, Brain K, Durand MA, Edwards A et al. . Fast and frugal tools for shared  
43 decision making: How to develop option grids. European Journal for Person Centered  
44 Health Care. 2013;1(1):240-5.  
45  
46  
47  
48 31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for  
49 Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in  
50 international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying  
4 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic*  
5 *Dis.* 1987;40(5):373-83.  
6  
7  
8  
9  
10 33. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J.*  
11 1965;14:61-5.  
12  
13  
14 34. Lawton MP, Brody EM. Assessment of older people: self-maintaining and  
15 instrumental activities of daily living. *Gerontologist.* 1969;9(3):179-86.  
16  
17  
18 35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for  
19 grading the cognitive state of patients for the clinician. *J Psychiatr Res.*  
20 1975;12(3):189-98.  
21  
22  
23  
24 36. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for  
25 Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire  
26 module: first results from a three-country field study. *J Clin Oncol.*  
27 1996;14(10):2756-68.  
28  
29  
30  
31 37. Johnson C, Fitzsimmons D, Gilbert J et al. Development of the European  
32 Organisation for Research and Treatment of Cancer quality of life questionnaire  
33 module for older people with cancer: The EORTC QLQ-ELD14. *Eur J Cancer.*  
34 2010;46(12):2242-52.  
35  
36  
37  
38  
39  
40  
41  
42  
43 38. EuroQol Group EuroQol—A new facility for the measurement of health-related  
44 quality of life  
45  
46  
47 39. Health Policy, 16 (1990), pp. 199–208. Brehaut JC, O'Connor AM, Wood TJ, Hack  
48 TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. *Med Decis*  
49 *Making.* 2003;23(4):281-92.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 40. Barr PJ, Thompson R, Walsh T, et al. The psychometric properties of CollaboRATE:  
4 a fast and frugal patient-reported measure of the shared decision-making process. J  
5 Med Internet Res. 2014;16(1):e2.  
6  
7  
8  
9  
10 41. Marteau TM, Bekker H. The development of a six-item short-form of the state scale  
11 of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992;31 (  
12 Pt 3):301-6.  
13  
14  
15  
16 42. Sepucha K, Ozanne E, Silvia K, et al. An approach to measuring the quality of breast  
17 cancer decisions. Patient Educ Couns. 2007;65(2):261-9.  
18  
19  
20  
21 43. Sepucha KR, Belkora JK, Chang Y, et al. Measuring decision quality: psychometric  
22 evaluation of a new instrument for breast cancer surgery. BMC Med Inform Decis  
23 Mak. 2012;12:51.  
24  
25  
26  
27 44. Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J  
28 Psychosom Res. 2006;60(6):631-7.  
29  
30  
31  
32 45. Carver CS. You want to measure coping but your protocol's too long: Consider the  
33 Brief COPE. International Journal of Behavioral Medicine. 1997; 4, 92-100. .  
34  
35  
36 46. Scott NW, Pea F. EORTC QLQ-C30 reference values. EORTC, Brussels. 2008.  
37  
38  
39 47. Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for determination of  
40 sample size and interpretation of the European Organisation for the Research and  
41 Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol.  
42 2011;29(1):89-96  
43  
44  
45  
46  
47 48. Campbell MJ & Walters SJ. How to Design, Analyse and Report Cluster Randomised  
48 Trials in Medicine and Health Related Research. Wiley and Sons. May 2014  
49  
50  
51  
52 49. StataCorp. 2015. *Stata Statistical Software: Release 14*. College Station, TX:  
53 StataCorp LP.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 50. Lloyd A & Joseph-Williams N. Case Study: Different outcomes from different  
4 approaches – Experience from the Cardiff MAGIC Programme, UK. In Elwyn G,  
5 Edwards A, Thompson R (eds.) Shared Decision Making in Health Care. 3<sup>rd</sup> edition.  
6  
7  
8  
9  
10 2016. Oxford: Oxford University Press.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# BMJ Open

## Bridging the Age Gap in Breast Cancer: Evaluation of decision support interventions for older women with operable breast cancer: protocol for a cluster randomised controlled trial.



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015133.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Mar-2017
Complete List of Authors:	<p>Collins, Karen; Sheffield Hallam University, Centre for Health and Social Care Research</p> <p>Lifford, Kate; Cochrane Institute of Primary Care &amp; Public Health, Burton, Maria; Sheffield Hallam University, Centre for Health and Social Care Research</p> <p>Reed, Malcolm; Brighton and Sussex Medical School, Edwards, Adrian; Cardiff University, Division of Population Medicine</p> <p>Ring, Alistair; Royal Marsden NHS Foundation Trust</p> <p>Brain, Kate; Cardiff University, Division of Population Medicine</p> <p>Harder, Helena; University of Sussex, SHORE-C Brighton and Sussex Medical School</p> <p>Robinson, Thomas; University of Leicester, Department of Cardiovascular Sciences</p> <p>Cheung, Kwok; University of Nottingham, School of Medicine</p> <p>Morgan, Jenna; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Audisio, Riccardo; University of Liverpool,</p> <p>Ward, Susan; The University of Sheffield, School of Health and Related Research</p> <p>Paul, Richards; The University of Sheffield, School of Health and Related Research</p> <p>Martin, Charleen; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Chater, Tim; The University of Sheffield, School of Health and Related Research</p> <p>Pemberton, Kirsty; The University of Sheffield, School of Health and Related Research</p> <p>Nettleship, Anthony; The University of Sheffield, School of Health and Related Research</p> <p>Murray, Christopher; The University of Sheffield, School of Health and Related Research</p> <p>Walters, Stephen; University of Sheffield, SCHARR</p> <p>Bortolami, Oscar; The University of Sheffield, School of Health and Related Research</p> <p>Armitage, Fiona; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Robert, Leonard; Imperial College Faculty of Medicine</p> <p>Revell, Deirdre; The University of Sheffield, North Trent Cancer Network Consumer Research Panel</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Gath, Jacqui; Independent Cancer Patients' Voice, Green, Tracy; The University of Sheffield, North Trent Cancer Network Consumer Research Panel Wyld, Lynda; University of Sheffield Medical School, Department of Oncology and Metabolism
<b>&lt;b&gt;Primary Subject Heading&lt;/b&gt;:</b>	Oncology
Secondary Subject Heading:	Health services research, Geriatric medicine
Keywords:	CHEMOTHERAPY, Cancer genetics < GENETICS, GERIATRIC MEDICINE, Risk management < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

or peer review only

SCHOLARONE™  
Manuscripts

1  
2  
3 TITLE: Bridging the Age Gap in Breast Cancer: Evaluation of decision support  
4 interventions for older women with operable breast cancer: protocol for a cluster randomised  
5 controlled trial.  
6  
7

8 Corresponding author:

9 Lynda Wyld,  
10 Department of Oncology & Metabolism  
11 The Medical School  
12 Beech Hill Road  
13 Sheffield  
14 S10 2RX  
15 UK  
16

17 Email: l.wyld@sheffield.ac.uk

18 Tel: +44 (0) 114 2259066  
19  
20

21  
22 Karen Collins, Centre for Health and Social Care Research, Sheffield Hallam University,  
23 Collegiate Crescent, Sheffield, UK

24  
25 Malcolm Reed, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton,  
26 UK  
27

28 Kate Lifford, Division of Population Medicine, School of Medicine, Cardiff University,  
29 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK  
30

31  
32 Maria Burton, Centre for Health and Social Care Research, Sheffield Hallam University,  
33 Collegiate Crescent, Sheffield, UK.  
34

35 Malcolm Reed, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton,  
36 UK.  
37

38 Adrian Edwards, Division of Population Medicine, School of Medicine, Cardiff University,  
39 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK  
40

41 Alistair Ring, Royal Marsden Hospital, London.

42  
43 Katherine Brain, Division of Population Medicine, School of Medicine, Cardiff University,  
44 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK  
45

46 Helena Harder, SHORE-C, University of Sussex, Falmer, Brighton, UK.  
47

48 Thompson Robinson, Department of Cardiovascular Sciences, Leicester Royal Infirmary,  
49 Infirmary Square, Leicester, LE2 7LX, UK.  
50

51  
52 Kwok Leung Cheung, School of Medicine, University of Nottingham, Royal Derby Hospital  
53 Centre, Uttoxeter Road, Derby DE22 3DT, UK.  
54

55 Jenna Morgan, Department of Oncology and Metabolism, University of Sheffield.  
56  
57  
58  
59  
60

1  
2  
3 Riccardo Audisio, Department of Surgery, University of Liverpool, St Helens Teaching  
4 Hospital, Marshalls Cross Road, St Helens, WA9 3DA, UK.

5  
6 Susan Ward, Department of Health Economics and Decision Science, School for Health and  
7 Related Research, University of Sheffield, Sheffield, UK.

8  
9 Paul Richards, Department of Health Economics and Decision Science, School for Health  
10 and Related Research, University of Sheffield, Sheffield, UK.

11  
12 Charlene Martin, Department of Oncology and Metabolism, University of Sheffield.

13  
14 Tim Chater, Clinical Trials Research Unit, School for Health and Related Research,  
15 University of Sheffield, Sheffield, UK.

16  
17 Kirsty Pemberton, Clinical Trials Research Unit, School for Health and Related Research,  
18 University of Sheffield, Sheffield, UK.

19  
20 Anthony Nettleship, Epigenesys, School for Health and Related Research, University of  
21 Sheffield, Sheffield, UK.

22  
23 Christopher Murray, Epigenesys, School for Health and Related Research, University of  
24 Sheffield, Sheffield, UK.

25  
26 Stephen Walters, Clinical Trials Research Unit, School for Health and Related Research,  
27 University of Sheffield, Sheffield, UK.

28  
29 Oscar Bortolami, Clinical Trials Research Unit, School for Health and Related Research,  
30 University of Sheffield, Sheffield, UK.

31  
32 Fiona Armitage, University of Sheffield, UK

33  
34 Robert Leonard, Imperial College Healthcare NHS Trust, St Mary's Hospital London, UK

35  
36 Jacqui Gath, Deirdre Revell, Tracy Green, Yorkshire and Humberside (formerly North Trent  
37 Cancer Network) Consumer Research Panel.

38  
39 Lynda Wyld, Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.  
40  
41  
42  
43  
44  
45

46  
47 Keywords: Breast cancer, decision aid, elderly, primary endocrine therapy, surgery,  
48 chemotherapy

49  
50  
51 Word count excluding title page, abstract, references, figures and tables: 4085/4000  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

Each year in the UK 16,000 women over the age of 70 develop breast cancer, of whom approximately 6,500 will ultimately die of the disease. Whilst breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable that co-morbidities/frailty rates are higher, which may increase the risks of some breast cancer treatments such as surgery and chemotherapy, many older women are healthy and may benefit from their use. Adjusting treatment regimens appropriately for age/co-morbidity/frailty is variable and largely non-evidence based, specifically with regard to rates of surgery for operable oestrogen receptor (ER) positive disease and rates of chemotherapy for high-risk disease.

### Methods and analysis

This multi-centre, parallel group, pragmatic cluster randomised controlled trial (2015-18) reported here, is nested within a larger ongoing “Age Gap Cohort Study” (2012-18; RP-PG-1209-10071), aims to evaluate the effectiveness of a complex intervention of decision support interventions (DESI) to assist in the treatment decision-making for early breast cancer in older women. The interventions include two patient decision aids (PtDAs) (primary endocrine therapy versus surgery/AET and chemotherapy versus no chemotherapy) and a clinical treatment outcomes algorithm for clinicians.

The primary outcome will be quality of life measured by EORTC QLQ C30. Secondary outcomes will include decision quality, coping, decision regret and treatment allocations.

1  
2  
3 Randomisation is at breast unit level (53 UK sites), stratified by high/ low primary endocrine  
4 therapy and chemotherapy rates. Women (n=1500) over 70 years with primary operable  
5 breast cancer will be recruited and followed up 6 weeks to 2 years post diagnosis with longer  
6 term cancer outcomes (overall survival, disease free survival) derived from cancer registry  
7 returns. Control arm: no change to usual practice. Intervention arm: usual practice plus  
8 DESIs adopted as standard care by clinicians.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **IRAS reference:** 115550  
20

21  
22 **Trial registration detail/number:**  
23

24 European Union Drug Regulating Authorities Clinical Trials (EudraCT) number 2015-  
25 004220-61  
26

27 Sponsor's Protocol Code Number Sheffield Teaching Hospitals STH17086  
28

29  
30 ISRCTN 32447\*  
31

32 \*The wider Age Gap study commenced as a cohort study in 2012/13, collecting prospective  
33 observational data on older women. At the time there was no requirement for registration on  
34 the ISRCTN database as the trial was approved prior to 2013 and was only a cohort study  
35 therefore the study team made public notification via the Cancer help database and more  
36 recently registered it on the EURDRACT database last year. The trial protocol was changed  
37 late 2015/2016 to convert the study to a cluster RCT and at that point registered the revised  
38 protocol with the ISRCTN.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- The two evidence based decision support interventions (DESI) for women over 70 years diagnosed with breast cancer who are offered a choice of primary endocrine therapy (PET) or surgery (plus adjuvant endocrine therapy, hereafter termed surgery/AET) or chemotherapy versus no chemotherapy is, to the best of our knowledge, the first of its kind worldwide.
- The web based clinical outcomes management algorithm is the first of its kind and allows patient age, co-morbidities, frailty and cancer characteristics to be considered in predicting breast cancer survival and cancer outcomes
- A limitations of the trial will potentially be selection bias from recruitment and poor uptake/utilisation of the DESI at intervention sites
- A second limitation may be an inability to demonstrate a benefit in terms of cancer survival rates without at least 5-10 years follow up or an overall survival advantage due to the competing causes of death in this age group.

## INTRODUCTION

### Background and rationale

Breast cancer is the most common cancer in women in the UK, with over 53,000 new cases being diagnosed in the UK each year [1]. Of these, 16,000 women will be over the age of 70, a figure which is rising steadily as the UK population ages [2]. Whilst breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes in this older age group of women. The UK lags significantly behind other European countries in its outcomes for these women. There is a wide variation in practice in the management of breast cancer in older women [3]. The gold standard of care for early breast cancer is surgical removal of the primary cancer (mastectomy or conservation surgery), and diagnostic or therapeutic axillary nodal surgery followed by stage and immunophenotype appropriate adjuvant therapies (chemotherapy, trastuzumab, anti-oestrogens and radiotherapy) to reduce the risks of disease recurrence. There is consistent evidence that older women are less likely to receive surgery, chemotherapy, radiotherapy and trastuzumab, based on the premise that there is less evidence of efficacy and a greater risk of treatment morbidity [4]. In the case of surgery, up to 40% of older women do not undergo surgery for their breast cancer, and their treatment is mainly with anti-oestrogen tablets alone, known as primary endocrine therapy (PET) [5]. Whilst it is inevitable that in older women, co-morbidities and frailty rates are higher, and which will increase the risks of some breast cancer treatments, such as surgery and chemotherapy, many older women are healthy and will benefit in terms of breast cancer outcomes, from their use. Selection of appropriate age, co-morbidity and frailty adjusted treatment regimens is highly variable, largely non-evidence based, and often fails to adequately consider the needs or wishes of patients. Two key areas of local practice variation are rates of surgery for operable oestrogen receptor (ER) positive disease and rates of chemotherapy for high risk



1  
2  
3 disease. PET rates vary fourfold between UK centres [3] and are not accounted for by case  
4  
5 mix adjustment. Similarly rates of chemotherapy vary 10-fold[4].  
6  
7

8  
9 Recent reports have advocated the use of PET only in the very old or frail[6]. Current  
10  
11 national guidelines state that patients with operable breast cancer should be treated with  
12  
13 surgery, and not PET, “irrespective of age” unless this is precluded by co-morbidities[7];  
14  
15 whilst the International Society of Geriatric Oncology (SIOG) and European Society of  
16  
17 Breast Cancer Specialists (EUSOMA) recommend that PET should only be offered to  
18  
19 patients with a “short estimated life expectancy (less than 2 to 3 years), who are considered  
20  
21 unfit for surgery... or who refuse surgery”[8]. However, as a large number of older women  
22  
23 are treated with PET in UK and other countries, it is not clear whether this guidance is being  
24  
25 followed consistently. PET is associated with high rates of patient satisfaction and low  
26  
27 treatment morbidity but in the medium and long term some women may need a change of  
28  
29 therapy once anti-oestrogen resistance develops [9]. Randomised trials and a recent Cochrane  
30  
31 review have shown that surgery (plus adjuvant anti-oestrogens herein after termed  
32  
33 surgery/AET) and PET have equivalent overall survival rates [10-11], However, for fitter  
34  
35 women with a longer predicted life expectancy, there is evidence that breast cancer specific  
36  
37 survival rates are inferior with PET [12]. For very frail women where surgery would be  
38  
39 unsafe or poorly tolerated, PET is the clear choice in women with oestrogen sensitive disease  
40  
41  
42  
43  
44 [12].

45  
46 For women at intermediate or higher risk of surgery complications there is a complex series  
47  
48 of trade-offs to be made for each patient. The decision must balance the risks of surgical  
49  
50 morbidity (pain, risks associated with hospitalisation, surgical complications) but with a  
51  
52 greater certainty of local disease control, against the minimal morbidity with PET but a risk  
53  
54 of later local disease progression and the need for a change of treatment to either surgery or  
55  
56 alternate anti-oestrogen therapy[13-15].  
57  
58  
59  
60

1  
2  
3 Chemotherapy utilisation is also very low in women over 70 (14%)[4] and almost non-  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Chemotherapy utilisation is also very low in women over 70 (14%)[4] and almost non-existent in women over 80, even in those where high phenotypic risk is present (high grade, node positive, ER negative, her-2 positive)[4]. Rates of chemotherapy can vary widely between UK breast units, between 6 and 60% in high risk women[16]. This reflects the fact that most of the randomised trials have upper age cut offs at age 70 or recruit very poorly in this age group, meaning there is little evidence of whether it is effective or not. In addition, there is evidence of an increased risk of significant complications such as neutropenic sepsis in older women [17]. This clearly suggests that guidelines for best practice are required. The primary tool used by oncologists to determine the likely benefit of chemotherapy on a patient level basis is Adjuvant!Online[18], although this has been shown to be inaccurate in older women[19]. The more recently developed PREDICT tool [20] performs better in this age group but has limited functionality for taking co-morbidity and frailty into account.

This cluster randomised trial will evaluate the implementation of two (“complex”) decision support interventions (DESI) designed to be used by both clinicians and patients to assist in the decision making about treatment for early breast cancer in older women.

### **The Bridging the Age Gap Study**

The Bridging the Age Gap study[21] is a NIHR funded programme of research (2012-18RP-PG-1209-10071) examining breast cancer management in older women with the ultimate aim of improving outcomes by providing high quality evidence to support treatment decision making in this age group.

The study protocol reported here focuses exclusively on the cluster randomised trial part of the wider Bridging the Age Gap Study [21]. The study group has developed two patient facing decision support interventions (DESI) based on a systematic evidence summary, expert reference group consultation, patient interviews [22-24] and questionnaires

1  
2  
3 about informational needs and preferences and extensive user- and field-testing with both  
4  
5 healthy older women and older women who had faced the decision relating to the choice of  
6  
7 surgery/AET or PET in frailer women with ER positive breast cancer, and the decision  
8  
9 regarding use of adjuvant chemotherapy in fitter women with high risk cancers. Each DESI  
10  
11 includes a clinician facing clinical management algorithm and two patient facing decision  
12  
13 aids (PtDAs). The clinician facing management algorithms derive from detailed cancer  
14  
15 registry outcome data linked to treatment related morbidity and patient and cancer  
16  
17 characteristics from the UK cancer registry (2002-2010) for two UK regions (Northern and  
18  
19 Yorkshire and East Midlands) which are representative of the UK population as a whole in  
20  
21 terms of demography, population structure and deprivation. This is a large diverse area,  
22  
23 representing 23% of the UK population [25]. These online algorithms allow patient age, co-  
24  
25 morbidities, frailty and cancer characteristics to be considered by a clinician in predicting  
26  
27 survival and cancer outcomes and to help inform breast cancer management decisions for  
28  
29 older women [25]. The PtDAs are in the form of a booklet and a (brief) option grid for the  
30  
31 clinical decision in question [26,27].  
32  
33  
34  
35  
36

37 The trial will evaluate these tools in a cluster randomised trial across 53 UK breast units  
38  
39 according to the study schematic (Figure 1).  
40  
41

42 The aims of this trial is to evaluate if, how and to what extent, the use of the DESIs  
43  
44 embedded as 'standard of care' within intervention-arm sites, improves QoL, decision quality  
45  
46 (integrating knowledge, attitudes and decision made), coping, illness representations and  
47  
48 reduces decision regret, thus indicating improved informed decision making of older women  
49  
50 about treatment options for their breast cancer.  
51  
52

53  
54 To our knowledge this is the first randomised controlled trial to have been undertaken to  
55  
56 explore this issue.  
57  
58  
59  
60

## Objectives

The objectives are to:

1. To assess the effectiveness of the implementation of DESIs [26][27] in clinical practice in terms of improving patient QoL, decision quality (integrating knowledge, attitudes and decision made), coping, illness representations and reducing decision regret, thus indicating improved informed decision making.
2. To determine if, how, or to what extent, the clinical outcomes management algorithm impacts on clinical decision making among clinicians (change in PET/surgery rates and chemotherapy rates).
3. To determine whether the DESIs are effective in improving short, medium and long term cancer outcomes in this age group of women, (treatment morbidity and overall and disease specific survival).
4. To assess the utility and uptake of the DESIs from the perspective of both clinicians and patients by undertaking a formal process evaluation.

## Hypotheses

1. Use of the DESIs will improve the quality of life in older women with operable breast cancer and ultimately improve cancer outcomes.

2. Older women faced with a choice of treatment decisions for their breast cancer will report an improved decision quality and shared decision-making experience and less decision regret using DESIs compared to older women who receive usual clinical decision making support.
3. Use of evidence based DESIs will improve short and longer term outcomes by improving treatment personalisation to a woman's health, fitness and cancer characteristics and by improving the quality of decision making, reduce the heterogeneity of practice across the UK.
4. Women in the intervention sites will express more positive illness representations (e.g. increased personal control, positive emotional consequences, less overall threat) and increased use of engagement coping strategies compared to women from the control sites.

## METHOD

### Study design and setting

This protocol follows the CONSORT statement guidelines for cluster trials [28].

This study is a multi-centre, parallel group, pragmatic cluster randomised controlled trial (2015-18) [29]. It is nested within a larger ongoing Bridging the Age Gap Cohort Study (2012-18) [21] (Figure 1) which is currently recruiting from 53 breast units within in the UK (observational cohort study of current UK management of older women with early breast cancer).

### Figure 1: Overview of the cluster randomised controlled trial

### The RCT study

The intervention comprises implementation of a package of two DESIs for the PET versus surgery/AET, or chemotherapy versus no chemotherapy decisions. Each DESI includes an online algorithm for treatment outcomes, and two patient decision aids (PtDAs)– a booklet and a brief option grid [26-27]. Each DESI is a complex intervention, including training for the clinician (breast surgeon, medical oncologist, breast care nurses) on the use of the algorithm (surgeons and medical oncologists only) or PtDAs, and the clinician and patient decide which, if any, of these elements they wish to use to assist the decision making process. The intention being for the intervention to be used as part of everyday clinical practice/pathway within the intervention sites.

Each online algorithm includes functionality to adjust outcome prediction according to patient age, co-morbidity, frailty, tumour stage and ER status and which gives outputs of 2 and 5 year overall and breast cancer specific survival. The algorithms were developed in the earlier phase of the Age Gap Study [25] and were designed to guide clinicians and their patients in the treatment of:

(1) frailer older women with ER positive breast cancer to optimise treatment with either PET or surgery/AET,

or

(2) fitter older women who have already had primary surgery and been found to have high risk cancer characteristics (e.g. ER negative, Her 2 positive or node positive breast cancer) to optimise treatment with either adjuvant chemotherapy or no adjuvant chemotherapy (note the term chemotherapy includes chemotherapy +/- trastuzumab if appropriate).

1  
2  
3 The algorithm is based on a computer model of predicted outcomes and variance caused by  
4 patient and disease parameters. Unlike existing web based algorithms for cancer treatment  
5 (Adjuvant! OnLine [19] or PREDICT[20]) which do not have the facility to specify frailty or  
6 comorbidity in detail (or at all), the Age Gap algorithm permits these factors to be taken into  
7 account. The Age Gap tool has been optimised for accuracy in this age group and has been  
8 based on analysis of data from over 20 000 UK women over the age of 70 derived from  
9 cancer registry data. The algorithm has built in educational materials (including several on  
10 line presentations, data sources, FAQs and an animated educational video). The online  
11 algorithm is designed to be used by clinicians to guide treatment decision making and its  
12 outputs can be printed off in a patient facing format that could be used in personalised patient  
13 counselling. The report provides specific survival estimates for each treatment option for an  
14 individual woman based on her personal and cancer characteristics. This works in much the  
15 same way as the print outs from Adjuvant!Online[19] or PREDICT[20] but in this case  
16 developed for the PET versus surgery/AET decision and with more detailed data entry  
17 relating to the woman's age and fitness level.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 Two PtDAs (PET versus surgery/AET[26] and chemotherapy versus no chemotherapy [27])  
38 have been developed during the earlier phase of the study [22-24]. The PtDAs comprise of an  
39 option grid [30] and a booklet for each decision. The option grid is a one page evidence-  
40 based summary of the treatment options alongside patients' frequently asked questions,  
41 helping patients to differentiate the key features, risks and benefits of treatment options in  
42 relation to their personal values and preferences. The option grid has been designed to be  
43 sufficiently brief for use in clinical encounters and accessible enough to support a better  
44 dialogue between patients and their clinical team [30]. The booklet provides information  
45 about both options including diagrams, side effects and potential risks and benefits. It also  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 includes a section to guide deliberation and encourage the patient to clarify their preferences  
4  
5 based around identifying “what is most important to them” [16].  
6  
7  
8

### 9 10 **Eligibility criteria**

#### 11 12 Inclusion criteria

- 13  
14  
15  
16 (1) Female  
17  
18 (2) Aged over 70 years of age at the time of diagnosis of cancer  
19  
20 (3) Primary operable (TNM categories V7: T1, T2, T3, N0, N1, M0), ER positive invasive  
21  
22 breast cancer (core biopsy or diagnostic incision biopsy)  
23  
24 (4) Ability to give informed consent and to read English  
25  
26  
27  
28  
29  
30

#### 31 32 Exclusion criteria

- 33 (1) Disease unsuitable for surgery e.g. inoperable, locally recurrent or metastatic disease.  
34  
35 (2) Previous invasive breast cancer within the last 5 years.  
36  
37 (3) Non-English speakers  
38  
39  
40  
41

### 42 **Data Collection and Outcomes.**

#### 43 44 Primary outcome measure

45  
46  
47 The primary outcome measure for the RCT is global health status/QoL score (questions  
48  
49 29+30 only of The European Organization for Research and Treatment of Cancer QLQ-C30  
50  
51 Reference Manual) (EORTC QLQ-C30) [31] at 6 weeks and 6 months post diagnosis/consent.  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 An independent data monitoring committee (DMC) comprising of 3 experienced academic  
4 clinicians oversees the study and monitors trial conduct and safety and potential harm and has  
5 access to all study data. The role being to provide recommendations for trial changes (or  
6 closure). Data collection is being undertaken by trained clinical staff within each of the  
7 participating sites. The study data manager and study monitor also undertake regular site  
8 visits to outline the study protocol, ensure protocol adherence and monitor data collection and  
9 completeness. Data collection for the study includes detailed information about the patient  
10 and their cancer at the time of diagnosis: age, comorbidity (Charlson co-morbidity index [32],  
11 frailty- The Barthel Index (ADL) [33] and instrumental activities of daily living scores  
12 (IADL) [34]), cognitive status (Mini-mental state examination-MMSE) [35], baseline QoL  
13 (EORTC QLQ C30 [31], EORTC breast cancer-specific QoL questionnaire (QLQ-BR23)  
14 [36], EORTC QoL questionnaire module for older people with cancer(QLQ-ELD14) [37],  
15 EuroQol Group EQ-5D[38]), tumour stage, grade and receptor status. Treatment details are  
16 recorded including the type of surgery to the breast and axilla, use of adjuvant therapies  
17 (chemotherapy, radiotherapy, trastuzumab and hormonal therapies), including doses and  
18 adverse effects recorded using the Common Terminology Criteria for Adverse Events  
19 grading system. Follow up is at baseline, 6 weeks, 6, 12, 18 and 24 months after  
20 diagnosis/consent. Cancer outcomes, QoL and adverse events are recorded at each visit and  
21 in the longer term, women are asked to sign a consent form to permit the trial to collect their  
22 Cancer Registry data which will be collected 5 and 10 years following diagnosis and consent  
23 to the study. These data will permit us to look at whether using the DESIs alters patterns of  
24 treatment decision making between control and intervention sites and whether these impact  
25 on long term outcomes. As such this is a uniquely detailed evaluation of such DESIs.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54  
55 In addition, specific questionnaires relating to patient choice and decision making will be  
56 administered. These will apply to all women offered a choice of either PET and surgery/AET  
57  
58  
59  
60

1  
2  
3 or chemotherapy versus no chemotherapy and are administered in relation to the time of their  
4  
5 treatment choice. Secondary outcomes measures here include decision regret (Decision  
6  
7 Regret Scale [39], shared decision making (CollaboRATE [40]), patient anxiety (Spielberger  
8  
9 short-form State scale of the State-Trait Anxiety Inventory[41], knowledge and preference  
10  
11 (knowledge,readiness to decide and preference measure[42-43]), illness perceptions (Brief  
12  
13 Illness Perceptions Questionnaire [44]) and Coping(brief COPE)[45]). Original data collected  
14  
15 are entered and kept on file within each of the study sites. This data is entered electronically  
16  
17 and stored securely onto password protected databases within local databases and the main  
18  
19 trial office. All records that contain names or other personal identifiers, such as locator forms  
20  
21 and informed consent forms, are stored separately from study records identified by code  
22  
23 number. Only the study steering and DMC have access to the full trial dataset Errors,  
24  
25 discrepancies or missing data are captured by the computer programme and the study data  
26  
27 manager checks and subsequently follows this up with participating sites.  
28  
29  
30  
31

32  
33 The timescales for each of these are shown in Table 1.  
34

35 Table 1.Data items relating to patient-based outcomes and cancer characteristics.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: Questionnaire Schedule**

Standard Age Gap Questionnaires	Baseline	6 weeks	6mths	12mths	18/24 mths	Long-term
IADL	*					
ADL	*					
MMSE	*					
ECOG perf. status	*					
Subjective Global Assessment	*					
Co-morbidity	*					
EQ5D	*	*	*	*	*	
QoL (EORTC-QLQ C30; QLQ-BR23 and (QLQ-ELD14)	*	*	*	*	*	
Decision quality	*	*				
RECIST if PET	*	*	*	*	*	
Registry data access						*
Tissue Access	*					*
Tumour details	*					
Treatment details	*	*	*	*	*	
Adverse events	*	*	*	*	*	
<b>New for DESI study</b> (if offered choice of either PET or surgery/AET, or chemotherapy/no chemotherapy)	Baseline (after consent for PET or surgery (AET or after consultation for chemo/no chemo, as applicable)	6 weeks after relevant treatment choice	6 months after relevant treatment choice			
Spielberger Anxiety		*	*			
Collaborate	*					
Decision Regret		*	*			
Knowledge readiness to decide and preference measures	*					
Brief IPQ		*	*			
Brief COPE		*	*			
<b>Process evaluation</b> (if taking part in process evaluation)						
Process evaluation questionnaire		*				

### Sample size calculation

The primary endpoint will be the global health status/QoL scale (questions 29 and 30 of the EORTC-QLQ-C30) at 6 months post baseline. Assuming a SD of 21 points for the global health status/QoL scale and a mean difference of 7 or more points on the global health status/QoL scale between the groups is of clinical/practical importance (a “small” standardised effect size of 0.33). With no allowance for clustering; for the PET versus surgery DESI comparison with 190 eligible women per group we will have a 90% power of detecting this difference or more as statistically significant between the groups at the 5% two-sided level. If we assume an intra-class correlation of 0.03 then allowing for the clustered RCT design we will need to recruit 10 women, eligible for using the decision aids, per cluster (i.e. 50 clusters x 10 women), 500 in total (this assumes a design effect of 1.3). With a 20% loss to follow-up by 6 months we need to recruit 13 women per cluster (50 clusters x 13 women) or 650 in total (325 per group).

### Randomisation

Randomisation is at breast unit level, stratified by high and low PET and chemotherapy rates. It was therefore not possible to blind the investigators or the study sites to the allocation of participants. Data for this stratification have been derived from the wider cohort study which has collected data on treatment rates for both PET versus surgery/AET and chemotherapy versus no chemotherapy.

**Control arm.** Usual standard practice for older women (>70 years) diagnosed with breast cancer with no change to normal treatment decision making practice.

1  
2  
3 **Intervention arm.** Usual standard practice for older women (>70 years) diagnosed with  
4 breast cancer plus optional clinician and patient access to the package of DESIs which will  
5 have been made available to these units to adopt as their standard of care.  
6  
7  
8

9  
10  
11 In the run in to the trial period (June–Dec 2015), clinical teams (clinicians, research and  
12 breast nurses) from the participating sites attended a training event to enhance concordance  
13 with the study protocol (control group) and provide additional training on shared decision  
14 making and the use of the DESIs (intervention group). This comprised of a 2 hour practical  
15 workshop which consisted of presentations, demonstrations and discussion based on the  
16 MAGIC programme [46].  
17  
18  
19  
20  
21  
22  
23

## 24 25 **Recruitment**

26  
27  
28  
29  
30 Potentially eligible women are identified by clinicians (breast surgeons, medical oncologists  
31 and specialist breast nurses) and research nursing staff within multi disciplinary teams of the  
32 study sites. Study packs are being given to eligible patients either following their clinical  
33 consultation where either PET or surgery/AET options or chemotherapy versus no  
34 chemotherapy options are discussed. Monthly study newsletters are sent to all participating  
35 sites to provide feedback to staff in order to maintain interest and recruitment to the study.  
36  
37 Any modifications to the original study protocol will be discussed with the DMEC and  
38 approvals sought from the funder and the ethics committee. Recruitment for the trial has  
39 now commenced and 750 women have been recruited over the 53 participating sites.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 51 **Data analysis**

52  
53  
54 The statistical analyses will be performed on an intention-to-treat basis comparing the DESI  
55 and control groups. All statistical exploratory tests will be two-tailed with  $p= 0.05$ . Baseline  
56  
57  
58  
59  
60

1  
2  
3 demographic (e.g. age), physical measurements, and health-related QoL data will be assessed  
4  
5 for comparability between the treatment groups. A marginal Generalised Linear Model  
6  
7 (GLM), with coefficients estimated using generalised estimating equations (GEE) with robust  
8  
9 standard errors and an exchangeable auto correlation matrix in STATA v13 will be used to  
10  
11 analyse the outcomes and allow for the clustered nature of the data. The exchangeable  
12  
13 correlation structure corresponds to an equal correlation model, meaning that the correlations  
14  
15 of the outcomes with a cluster, i.e. breast centres, are the same. For continuous outcomes,  
16  
17 such as mean global health status/QoL score (questions 29+30 of EORTC QLQ-C30 [31]) at  
18  
19 6 months post-diagnosis/consent intervention, knowledge score and preference for treatment  
20  
21 score, an identity link with a Normal distribution for the outcome will be used. Estimates for  
22  
23 the treatment group coefficient from this regression model will be reported along with their  
24  
25 associated 95% confidence interval. In the event of differences between the intervention and  
26  
27 control groups with respect to baseline demographic, physical, and health-related QoL  
28  
29 measurements, then these covariates will be used in the GLM to adjust the treatment effect  
30  
31 for these variables. The adjusted regression coefficient estimate for the treatment group  
32  
33 parameter along with its 95% confidence interval (CI) will then be reported.  
34  
35  
36  
37  
38

39 For the other secondary outcomes, at 6 weeks and 6 months, such as the other dimensions of  
40  
41 the EORTC QLQ C30 [31], the EORTC QLQ-BR23 [36] and EORTC QLQ-ELD14 [37] the  
42  
43 mean QoL dimension scores will be compared between the intervention and control groups,  
44  
45 using similar models.  
46  
47  
48

49 A series of exploratory sub group analyses using a marginal GLM with coefficients estimated  
50  
51 using GEE with robust standard errors and an exchangeable auto correlation matrix, with the  
52  
53 primary outcome the mean Global health status/QoL score (questions 29+30 of EORTC  
54  
55 QLQ-C30 [31]) at 6-month post-diagnosis/consent randomisation as the response will be  
56  
57 carried out. An interaction statistical test between the randomised intervention group and  
58  
59  
60

1  
2  
3 subgroup to directly examine the strength of evidence for the treatment difference between  
4  
5 the treatment groups (Intervention versus Control) varying between subgroups will be  
6  
7 undertaken. Age subgroup (75-79, 80-84, 85-89 and 90+ years) and co-morbidity levels  
8  
9 (based on the modified Charlson co-morbidity score [32]) will be the only a priori defined  
10  
11 sub groups to be considered for interaction test. Sub group analysis will be performed  
12  
13 regardless of the statistical significance on the overall intervention effect (intervention versus  
14  
15 control).

#### 16 17 18 19 Missing primary outcome data

20  
21  
22 A sensitivity analysis using a variety of imputation methods, to impute any missing primary  
23  
24 outcome data (6-month EORTC QLQ-C30 [31] global health status/QoL score) will be  
25  
26 performed. The imputation methods will include last observation carried forward, regression  
27  
28 and multiple imputation. The estimates of the treatment effect and its associated confidence  
29  
30 interval, from the various imputation methods, will be graphically displayed alongside the  
31  
32 results for the observed data.  
33  
34  
35

#### 36 37 **Process Evaluation**

38  
39  
40 Running alongside the main study, a detailed mixed methods process evaluation is being  
41  
42 undertaken at 16 sites to assess the implementation of the DESIs(fidelity to the trial protocol)  
43  
44 to consider the DESIs' usefulness and acceptability and examine the facilitators and barriers  
45  
46 to embedding them into everyday clinical practice. A random selection of breast units was  
47  
48 made stratified by trial arm and recruitment rate to the cohort study (high/low  
49  
50 PET/surgery/chemo rates).  
51  
52

53  
54 In summary, the Age Gap study [21] aims to improving outcomes of older women diagnosed  
55  
56 with breast cancer by providing high quality evidence to support treatment decision making  
57  
58  
59  
60

1  
2  
3 in this age group. The two evidence based DESIs each include a clinical management  
4 algorithm and two patient decision aids (PtDAs) in the form of a booklet and a (brief) option  
5 grid for the clinical decision in question. These online algorithms will allow patient age, co-  
6 morbidity, frailty and cancer characteristics to be considered by a clinician in predicting  
7 survival and cancer outcomes and to help inform breast cancer management decisions for  
8 older women.  
9  
10  
11  
12  
13  
14  
15  
16

### 17 **ETHICS AND DISSEMINATION**

20 The study received ethics approval from the London South East NHS Research Ethics  
21 Committee (12/LO/1808) and research and development approvals gained from all UK sites.  
22  
23 A full study report will be made publicly available once approved by the funders. The  
24 findings from the trial will be presented at major scientific conferences and published in  
25 international peer reviewed scientific journals.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Acknowledgments

The authors are grateful to all participating sites, and specifically site principal investigators (PI) who have or who are currently contributing to the RCT

**Competing interests:** None declared

**Funding:** This work is supported by National Institute of Health Research Programme Grant [grant number RP-PG-1209-10071]

**Contributors** LW, KC and MR were overall project leads. Decision aid development and testing KL, MB, KC, LW, MR, AE, KB, JG, DR, FA, HH. Trial management: LW, CM, TC, KP. On line tool development: LW, SW, PR, AN, CM, MB, JM. Statistical advice: SW, OB. Trial management group: LW, MR, KC, TR, KLC, AR, etc. Chemotherapy advisors: AR, RL, HH. All authors have contributed to reading and approved the final manuscript.

**Provenance and peer review:**Not commissioned; externally peer reviewed

**Open access:**This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

1. Cancer Research UK breast cancer incidence [accessed 1/11/2016] Available from <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer>
2. Office for National Statistics. New cases of cancer diagnosed in England, 2014: selected sites by age group and sex. Office for National Statistics 2010[accessed 1/11/2016] Available from <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregistrationssummarytables/previousReleases>
3. Morgan J, Richards P, Ward S et al (2015) Case mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer. *British Journal of Surgery*. 102 (9), 1056-1063.
4. Ring A, Harder H, Langridge C et al. Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. *Ann Oncol*. 2013;24(5):1211-9.
5. BCCOM. Breast Cancer Clinical Outcome Measures (BCCOM) Project. Birmingham, UK; 2007
6. Chakrabarti J, Kenny FS, Syed BM, et al. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer- final results at 20-year follow-up. *Crit Rev OncolHematol* 2011;78:260-264.
7. NICE. Early and locally advanced breast cancer: full guideline. Cardiff: National Collaborating Centre for Cancer; 2009.
8. Biganzoli L, Wildiers H, Oakman C. et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology

- 1  
2  
3 (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). *Lancet Oncol*  
4  
5 2012;13:e148-e160.  
6  
7  
8 9. Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older  
9  
10 women with operable breast cancer - a comparison of randomised controlled trial and  
11  
12 cohort study findings. *Eur J SurgOncol*. 2014;40(6):676-84.  
13  
14  
15 10. Glas de, NA, Jonker JM, Bastiaannet E, et al. Impact of omission of surgery on  
16  
17 survival of older patients with breast cancer. *Br J Surg*. 2014;101(11):1397-404.  
18  
19  
20 11. Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone  
21  
22 for older women with operable breast cancer: cochrane review. *Br J Cancer*.  
23  
24 2007;96(7):1025-9.  
25  
26 12. Morgan J, Wyld L, Collins K, et al. Surgery versus primary endocrine therapy for  
27  
28 operable primary breast cancer in elderlywomen (70 years plus). *Cochrane Db Syst*  
29  
30 *Rev* 2014;5:CD004272.  
31  
32  
33 13. Audisio RA, Wyld L. No standard is set for older women with breast cancer. *Eur J*  
34  
35 *SurgOncol* 2015 May; 41 (5): 607  
36  
37  
38 14. Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older  
39  
40 women with operable breast cancer - a comparison of randomised controlled trial and  
41  
42 cohort study findings. *Eur J SurgOncol*. 2014;40(6):676-84.  
43  
44  
45 15. Hille U, Soergel P, Länger F, et al. Aromatase inhibitors as solely treatment in  
46  
47 postmenopausal breast cancer patients. *Breast J* 2012;18(2):145-50.  
48  
49  
50 16. Elwyn G, Frosch D, Thomson R et al. Shared decision making: a model for clinical  
51  
52 practice. *J Gen Intern Med* 2012 Oct; 27 (10): 1361-7.  
53  
54  
55 17. NICE Clinical guideline. Neutropenic sepsis: prevention and management in people  
56  
57 with cancer. CG151]Published date: September 2012  
58  
59  
60

- 1  
2  
3 18. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making  
4 decisions about adjuvant therapy for women with early breast cancer. *J Clin Oncol.*  
5 2001;19(4):980-91.  
6  
7  
8  
9  
10 19. deGlas NA, van de Water W, Engelhardt EG, et al. Validity of Adjuvant! Online  
11 program in older patients with breast cancer: a population-based study. *Lancet Oncol.*  
12 2014;15(7):722-9.  
13  
14  
15  
16 20. Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic  
17 model that predicts survival following surgery for invasive breast cancer. *Breast*  
18 *Cancer Res.* 2010; 12(1): R1. Published online 2010 January 6. doi: 10.1186/bcr2464.  
19  
20  
21  
22  
23  
24  
25  
26 21. Wyld L, Reed MWR, Collins K et al .Bridging the Age Gap in Breast Cancer:  
27 Improving outcomes for older women NIHR Programme grant 2012-17RP-PG-1209-  
28 10071[Accessed 18/11/ 2016] Available at [http://www.nihr.ac.uk/funding/funded-](http://www.nihr.ac.uk/funding/funded-research/funded-research.htm?postid=2237)  
29  
30  
31  
32  
33  
34 22. Lifford KJ, Witt J, Burton M, et al. Understanding older women's decision making  
35 and coping in the context of breast cancer treatment. *BMC Medical Informatics &*  
36  
37  
38  
39  
40  
41 23. Burton M, Collins K, Caldon LJM et al. Information Needs of Older Women Faced  
42 With a Choice of Primary Endocrine Therapy or Surgery for Early Stage Breast  
43  
44  
45  
46  
47  
48 24. Burton M, Collins K, Lifford K et al. The information and decision support needs of  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 25. Richards P, Ward S, Morgan J, et al. The use of surgery in the treatment of ER+ early  
4 stage breast cancer in England: variation by time, age and patient characteristics.  
5 European Journal of Surgical Oncology. 2016; 42(4) 489-96.  
6  
7  
8  
9  
10 26. Deciding about your breast cancer treatment: surgery and hormone-blocking pills or  
11 hormone-blocking pills only. Cardiff University, The University of Sheffield,  
12 Sheffield Hallam University developed as part of the Bridging the Age Gap Study  
13 (RP-PG-1209-10071) August 2015.  
14  
15  
16  
17  
18 27. Deciding about your breast cancer treatment: chemotherapy or no chemotherapy. The  
19 University of Sheffield ,Brighton and Sussex Medical School, Sheffield Hallam  
20 University and Cardiff Universityas part of the Bridging the Age Gap Study (RP-  
21 PG-1209-10071) January 2016.  
22  
23  
24  
25  
26  
27 28. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated  
28 guidelines for reporting parallel group randomized trials. Ann Intern Med.  
29 2010;152(11):726-32.  
30  
31  
32  
33  
34 29. Wyld L, Reed MWR, Collins K on behalf of the Age Gap study. A multi-centre, parallel  
35 group, pragmatic cluster randomised controlled trial NIHR Programme grant RP-PG-1209-  
36 1007.EUDRACT No:2015-004220-61  
37  
38  
39  
40  
41  
42 30. Marrin k, Brain K, Durand MA, Edwards A et al. . Fast and frugal tools for shared  
43 decision making: How to develop option grids.European Journal for Person Centered  
44 Health Care. 2013;1(1):240-5.  
45  
46  
47  
48 31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for  
49 Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in  
50 international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying  
4 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic*  
5 *Dis.* 1987;40(5):373-83.  
6  
7  
8  
9  
10 33. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J.*  
11 1965;14:61-5.  
12  
13  
14 34. Lawton MP, Brody EM. Assessment of older people: self-maintaining and  
15 instrumental activities of daily living. *Gerontologist.* 1969;9(3):179-86.  
16  
17  
18 35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for  
19 grading the cognitive state of patients for the clinician. *J Psychiatr Res.*  
20 1975;12(3):189-98.  
21  
22  
23  
24 36. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for  
25 Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire  
26 module: first results from a three-country field study. *J Clin Oncol.*  
27 1996;14(10):2756-68.  
28  
29  
30  
31 37. Johnson C, Fitzsimmons D, Gilbert J et al. Development of the European  
32 Organisation for Research and Treatment of Cancer quality of life questionnaire  
33 module for older people with cancer: The EORTC QLQ-ELD14. *Eur J Cancer.*  
34 2010;46(12):2242-52.  
35  
36  
37  
38  
39  
40  
41  
42  
43 38. EuroQol Group EuroQol—A new facility for the measurement of health-related  
44 quality of life  
45  
46  
47 39. Health Policy, 16 (1990), pp. 199–208. Brehaut JC, O'Connor AM, Wood TJ, Hack  
48 TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. *Med Decis*  
49 *Making.* 2003;23(4):281-92.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 40. Barr PJ, Thompson R, Walsh T, et al. The psychometric properties of CollaboRATE:  
4 a fast and frugal patient-reported measure of the shared decision-making process. J  
5 Med Internet Res. 2014;16(1):e2.  
6  
7  
8  
9  
10 41. Marteau TM, Bekker H. The development of a six-item short-form of the state scale  
11 of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992;31 ( Pt 3):301-6.  
12  
13  
14  
15  
16 42. Sepucha K, Ozanne E, Silvia K, et al. An approach to measuring the quality of breast  
17 cancer decisions. Patient Educ Couns. 2007;65(2):261-9.  
18  
19  
20  
21 43. Sepucha KR, Belkora JK, Chang Y, et al. Measuring decision quality: psychometric  
22 evaluation of a new instrument for breast cancer surgery. BMC Med Inform Decis  
23 Mak. 2012;12:51.  
24  
25  
26  
27 44. Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J  
28 Psychosom Res. 2006;60(6):631-7.  
29  
30  
31  
32 45. Carver CS. You want to measure coping but your protocol's too long: Consider the  
33 Brief COPE. International Journal of Behavioral Medicine. 1997; 4, 92-100. .  
34  
35  
36 46. Lloyd A & Joseph-Williams N. Case Study: Different outcomes from different  
37 approaches – Experience from the Cardiff MAGIC Programme, UK. In Elwyn G,  
38 Edwards A, Thompson R (eds.) Shared Decision Making in Health Care. 3<sup>rd</sup> edition.  
39 2016. Oxford: Oxford University Press.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: Overview of the Cluster randomised Controlled Trial

335x182mm (300 x 300 DPI)

review only





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	Within main protocol but N/A for journal
Protocol version	3	Date and version identifier	Within main protocol but N/A for journal
Funding	4	Sources and types of financial, material, and other support	23
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	23
	5b	Name and contact information for the trial sponsor	4
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	4

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Within main protocol but N/A for journal
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	6-8
	6b	Explanation for choice of comparators	18,19
Objectives	7	Specific objectives or hypotheses	10-11
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	11
<b>Methods: Participants, interventions, and outcomes</b>			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	11
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	14
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	12-13
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	15
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	19
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A

1				
2				
3	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	15-17
4				
5				
6				
7				
8	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	17
9				
10				
11	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	18
12				
13				
14	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	19
15				
16				

### 17 **Methods: Assignment of interventions (for controlled trials)**

#### 18 Allocation:

19				
20				
21	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	18
22				
23				
24				
25				
26	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	N/A 18
27				
28				
29				
30	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	18
31				
32				
33				
34	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A 18
35				
36				
37		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
38				
39				

### 40 **Methods: Data collection, management, and analysis**

1				
2				
3	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	14-16
4	methods		processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of	
5			study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	
6			Reference to where data collection forms can be found, if not in the protocol	
7				
8		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	17
9			collected for participants who discontinue or deviate from intervention protocols	
10				
11	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality	16
12			(eg, double data entry; range checks for data values). Reference to where details of data management	
13			procedures can be found, if not in the protocol	
14				
15	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the	19-21
16			statistical analysis plan can be found, if not in the protocol	
17				
18		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	21
19				
20		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any	21
21			statistical methods to handle missing data (eg, multiple imputation)	
22				
23				
24	<b>Methods: Monitoring</b>			
25				
26	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of	15
27			whether it is independent from the sponsor and competing interests; and reference to where further details	
28			about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not	
29			needed	
30				
31		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim	17
32			results and make the final decision to terminate the trial	
33				
34				
35	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse	15
36			events and other unintended effects of trial interventions or trial conduct	
37				
38	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent	15,17
39			from investigators and the sponsor	
40				
41				
42	<b>Ethics and dissemination</b>			
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	22
4				
5				
6	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	15
7				
8				
9				
10	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	19
11				
12				
13		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
14				
15				
16	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	16
17				
18				
19	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	23
20				
21				
22	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	15
23				
24				
25	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
26				
27				
28	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	22
29				
30		31b	Authorship eligibility guidelines and any intended use of professional writers	23
31				
32		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	23
33				
34				
35				
36				
37	<b>Appendices</b>			
38				
39	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Provided in main protocol not journal
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
----------------------	----	--	-----

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

# BMJ Open

## Bridging the Age Gap in Breast Cancer: Evaluation of decision support interventions for older women with operable breast cancer: protocol for a cluster randomised controlled trial.



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015133.R2
Article Type:	Protocol
Date Submitted by the Author:	18-May-2017
Complete List of Authors:	<p>Collins, Karen; Sheffield Hallam University, Centre for Health and Social Care Research</p> <p>Reed, Malcolm; Brighton and Sussex Medical School,</p> <p>Lifford, Kate; Cochrane Institute of Primary Care &amp; Public Health,</p> <p>Burton, Maria; Sheffield Hallam University, Centre for Health and Social Care Research</p> <p>Edwards, Adrian; Cardiff University, Division of Population Medicine</p> <p>Ring, Alistair; Royal Marsden NHS Foundation Trust</p> <p>Brain, Kate; Cardiff University, Division of Population Medicine</p> <p>Harder, Helena; University of Sussex, SHORE-C Brighton and Sussex Medical School</p> <p>Robinson, Thomas; University of Leicester, Department of Cardiovascular Sciences</p> <p>Cheung, Kwok; University of Nottingham, School of Medicine</p> <p>Morgan, Jenna; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Audisio, Riccardo; University of Liverpool,</p> <p>Ward, Susan; The University of Sheffield, School of Health and Related Research</p> <p>Paul, Richards; The University of Sheffield, School of Health and Related Research</p> <p>Martin, Charleen; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Chater, Tim; The University of Sheffield, School of Health and Related Research</p> <p>Pemberton, Kirsty; The University of Sheffield, School of Health and Related Research</p> <p>Nettleship, Anthony; The University of Sheffield, School of Health and Related Research</p> <p>Murray, Christopher; The University of Sheffield, School of Health and Related Research</p> <p>Walters, Stephen; University of Sheffield, SCHARR</p> <p>Bortolami, Oscar; The University of Sheffield, School of Health and Related Research</p> <p>Armitage, Fiona; University of Sheffield Medical School, Department of Oncology and Metabolism</p> <p>Robert, Leonard; Imperial College Faculty of Medicine</p> <p>Gath, Jacqui; Independent Cancer Patients' Voice,</p> <p>Revell, Deirdre; The University of Sheffield, North Trent Cancer Network</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Consumer Research Panel Green, Tracy; The University of Sheffield, North Trent Cancer Network Consumer Research Panel Wyld, Lynda; University of Sheffield Medical School, Department of Oncology and Metabolism
<b>Primary Subject Heading:</b>	Oncology
<b>Secondary Subject Heading:</b>	Health services research, Geriatric medicine
<b>Keywords:</b>	CHEMOTHERAPY, Cancer genetics < GENETICS, GERIATRIC MEDICINE, Risk management < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

or peer review only

SCHOLARONE™  
Manuscripts



1  
2  
3 TITLE: Bridging the Age Gap in Breast Cancer: Evaluation of decision support  
4 interventions for older women with operable breast cancer: protocol for a cluster randomised  
5 controlled trial.  
6  
7

8  
9 Corresponding author:

10 Lynda Wyld,

11 Department of Oncology & Metabolism

12 The Medical School

13 Beech Hill Road

14 Sheffield

15 S10 2RX

16 UK

17 Email: l.wyld@sheffield.ac.uk

18 Tel: +44 (0) 114 2259066  
19  
20  
21  
22  
23  
24  
25  
26

27 Karen Collins, Centre for Health and Social Care Research, Sheffield Hallam University,  
28 Collegiate Crescent, Sheffield, UK

29 Malcolm Reed, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton,  
30 UK.  
31

32 Kate Lifford, Division of Population Medicine, School of Medicine, Cardiff University,  
33 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK

34 Maria Burton, Centre for Health and Social Care Research, Sheffield Hallam University,  
35 Collegiate Crescent, Sheffield, UK.  
36

37 Adrian Edwards, Division of Population Medicine, School of Medicine, Cardiff University,  
38 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK

39 Alistair Ring, Royal Marsden Hospital, London.

40 Katherine Brain, Division of Population Medicine, School of Medicine, Cardiff University,  
41 Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK

42 Helena Harder, SHORE-C, University of Sussex, Falmer, Brighton, UK.

43 Thompson Robinson, Department of Cardiovascular Sciences, Leicester Royal Infirmary,  
44 Infirmary Square, Leicester, LE2 7LX, UK.  
45

46 Kwok Leung Cheung, School of Medicine, University of Nottingham, Royal Derby Hospital  
47 Centre, Uttoxeter Road, Derby DE22 3DT, UK.  
48

49 Jenna Morgan, Department of Oncology and Metabolism, University of Sheffield.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Riccardo Audisio, Department of Surgery, University of Liverpool, St Helens Teaching  
4 Hospital, Marshalls Cross Road, St Helens, WA9 3DA, UK.

5  
6 Susan Ward, Department of Health Economics and Decision Science, School for Health and  
7 Related Research, University of Sheffield, Sheffield, UK.

8  
9 Paul Richards, Department of Health Economics and Decision Science, School for Health  
10 and Related Research, University of Sheffield, Sheffield, UK.

11  
12 Charlene Martin, Department of Oncology and Metabolism, University of Sheffield.

13  
14 Tim Chater, Clinical Trials Research Unit, School for Health and Related Research,  
15 University of Sheffield, Sheffield, UK.

16  
17 Kirsty Pemberton, Clinical Trials Research Unit, School for Health and Related Research,  
18 University of Sheffield, Sheffield, UK.

19  
20 Anthony Nettleship, Epigenesys, School for Health and Related Research, University of  
21 Sheffield, Sheffield, UK.

22  
23 Christopher Murray, Epigenesys, School for Health and Related Research, University of  
24 Sheffield, Sheffield, UK.

25  
26 Stephen Walters, Clinical Trials Research Unit, School for Health and Related Research,  
27 University of Sheffield, Sheffield, UK.

28  
29 Oscar Bortolami, Clinical Trials Research Unit, School for Health and Related Research,  
30 University of Sheffield, Sheffield, UK.

31  
32 Fiona Armitage, University of Sheffield, UK

33  
34 Robert Leonard, Imperial College Healthcare NHS Trust, St Mary's Hospital London, UK

35  
36 Jacqui Gath, Deirdre Revell, Tracy Green, Yorkshire and Humberside (formerly North Trent  
37 Cancer Network) Consumer Research Panel.

38  
39 Lynda Wyld, Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.  
40  
41  
42  
43  
44  
45

46  
47 Keywords: Breast cancer, decision aid, elderly, primary endocrine therapy, surgery,  
48 chemotherapy

49  
50  
51 Word count excluding title page, abstract, references, figures and tables: 4085/4000  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

Whilst breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes among the older age group. It is inevitable that co-morbidities/frailty rates are higher, which may increase the risks of some breast cancer treatments such as surgery and chemotherapy, many older women are healthy and may benefit from their use. Adjusting treatment regimens appropriately for age/co-morbidity/frailty is variable and largely non-evidence based, specifically with regard to rates of surgery for operable oestrogen receptor (ER) positive disease and rates of chemotherapy for high-risk disease.

### Methods and analysis

This multi-centre, parallel group, pragmatic cluster randomised controlled trial (2015-18) reported here, is nested within a larger ongoing “Age Gap Cohort Study” (2012-18; RP-PG-1209-10071), aims to evaluate the effectiveness of a complex intervention of decision support interventions (DESIs) to assist in the treatment decision-making for early breast cancer in older women. The interventions include two patient decision aids (PtDAs) (primary endocrine therapy versus surgery/AET and chemotherapy versus no chemotherapy) and a clinical treatment outcomes algorithm for clinicians.

The primary outcome will be quality of life measured by EORTC QLQ C30. Randomisation is at breast unit level (53 UK sites), stratified by high/ low primary endocrine therapy and chemotherapy rates. Women (n=1500) over 70 years with primary operable breast cancer will be recruited and followed up 6 weeks to 2 years post diagnosis with longer term cancer outcomes (overall survival, disease free survival) derived from cancer registry returns.

1  
2  
3 Control arm: no change to usual practice. Intervention arm: usual practice plus DESIs  
4  
5 adopted as standard care by clinicians.  
6  
7

## 8 9 **ETHICS AND DISSEMINATION**

10  
11 National and local ethics committee approval were obtained for all UK participating sites. Results  
12  
13 from the trial will be submitted for publication in international peer reviewed scientific journals.  
14  
15

16  
17  
18  
19  
20 **IRAS reference:** 115550  
21

### 22 23 **Trial registration detail/number:**

24  
25 European Union Drug Regulating Authorities Clinical Trials (EudraCT) number 2015-  
26  
27 004220-61  
28

29  
30 Sponsor's Protocol Code Number Sheffield Teaching Hospitals STH17086

31  
32 ISRCTN 32447\*  
33

34 \*The wider Age Gap study commenced as a cohort study in 2012/13, collecting prospective  
35  
36 observational data on older women. At the time there was no requirement for registration on  
37  
38 the ISRCTN database as the trial was approved prior to 2013 and was only a cohort study  
39  
40 therefore the study team made public notification via the Cancer help database and more  
41  
42 recently registered it on the EURDRACT database last year. The trial protocol was changed  
43  
44 late 2015/2016 to convert the study to a cluster RCT and at that point registered the revised  
45  
46 protocol with the ISRCTN.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- The two evidence based decision support interventions (DESIs) for women over 70 years diagnosed with breast cancer who are offered a choice of primary endocrine therapy (PET) or surgery (plus adjuvant endocrine therapy, hereafter termed surgery/AET) or chemotherapy versus no chemotherapy is, to the best of our knowledge, the first of its kind worldwide.
- The web based clinical outcomes management algorithm is the first of its kind and allows patient age, co-morbidities, frailty and cancer characteristics to be considered in predicting breast cancer survival and cancer outcomes
- A limitations of the trial will potentially be selection bias from recruitment and poor uptake/utilisation of the DESIs at intervention sites
- A second limitation may be an inability to demonstrate a benefit in terms of cancer survival rates without at least 5-10 years follow up or an overall survival advantage due to the competing causes of death in this age group.

## INTRODUCTION

### Background and rationale

Breast cancer is the most common cancer in women in the UK, with over 53,000 new cases being diagnosed in the UK each year [1]. Of these, 16,000 women will be over the age of 70, a figure which is rising steadily as the UK population ages[2]. Whilst breast cancer outcomes are improving steadily in younger women due to advances in screening and improved therapies, there has been little change in outcomes in this older age group of women. The UK lags significantly behind other European countries in its outcomes for these women. There is a wide variation in practice in the management of breast cancer in older women[3]. The gold standard of care for early breast cancer is surgical removal of the primary cancer (mastectomy or conservation surgery), and diagnostic or therapeutic axillary nodal surgery followed by stage and immunophenotype appropriate adjuvant therapies (chemotherapy, trastuzumab, anti-oestrogens and radiotherapy) to reduce the risks of disease recurrence. There is consistent evidence that older women are less likely to receive surgery, chemotherapy, radiotherapy and trastuzumab, based on the premise that there is less evidence of efficacy and a greater risk of treatment morbidity[4]. In the case of surgery, up to 40% of older women do not undergo surgery for their breast cancer, and their treatment is mainly with anti-oestrogen tablets alone, known as primary endocrine therapy (PET)[5]. Whilst it is inevitable that in older women, co-morbidities and frailty rates are higher, and which will increase the risks of some breast cancer treatments, such as surgery and chemotherapy, many older women are healthy and will benefit in terms of breast cancer outcomes, from their use. Selection of appropriate age, co-morbidity and frailty adjusted treatment regimens is highly variable, largely non-evidence based, and often fails to adequately consider the needs or wishes of patients. Two key areas of local practice variation are rates of surgery for operable oestrogen receptor (ER) positive disease and rates of chemotherapy for high risk

1  
2  
3 disease. PET rates vary fourfold between UK centres [3] and are not accounted for by case  
4  
5 mix adjustment. Similarly rates of chemotherapy vary 10-fold[4].  
6  
7

8  
9 Recent reports have advocated the use of PET only in the very old or frail[6]. Current  
10  
11 national guidelines state that patients with operable breast cancer should be treated with  
12  
13 surgery, and not PET, “irrespective of age” unless this is precluded by co-morbidities [7];  
14  
15 whilst the International Society of Geriatric Oncology (SIOG) and European Society of  
16  
17 Breast Cancer Specialists (EUSOMA) recommend that PET should only be offered to  
18  
19 patients with a “short estimated life expectancy (less than 2 to 3 years), who are considered  
20  
21 unfit for surgery... or who refuse surgery”[8]. However, as a large number of older women  
22  
23 are treated with PET in UK and other countries, it is not clear whether this guidance is being  
24  
25 followed consistently. PET is associated with high rates of patient satisfaction and low  
26  
27 treatment morbidity but in the medium and long term some women may need a change of  
28  
29 therapy once anti-oestrogen resistance develops [9]. Randomised trials and a recent Cochrane  
30  
31 review have shown that surgery (plus adjuvant anti-oestrogens herein after termed  
32  
33 surgery/AET) and PET have equivalent overall survival rates [10-11], However, for fitter  
34  
35 women with a longer predicted life expectancy, there is evidence that breast cancer specific  
36  
37 survival rates are inferior with PET [12]. For very frail women where surgery would be  
38  
39 unsafe or poorly tolerated, PET is the clear choice in women with oestrogen sensitive disease  
40  
41  
42  
43  
44 [12].

45  
46 For women at intermediate or higher risk of surgery complications there is a complex series  
47  
48 of trade-offs to be made for each patient. The decision must balance the risks of surgical  
49  
50 morbidity (pain, risks associated with hospitalisation, surgical complications) but with a  
51  
52 greater certainty of local disease control, against the minimal morbidity with PET but a risk  
53  
54 of later local disease progression and the need for a change of treatment to either surgery or  
55  
56 alternate anti-oestrogen therapy[13-15].  
57  
58  
59  
60

1  
2  
3 Chemotherapy utilisation is also very low in women over 70 (14%)[4] and almost non-  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Chemotherapy utilisation is also very low in women over 70 (14%)[4] and almost non-existent in women over 80, even in those where high phenotypic risk is present (high grade, node positive, ER negative, her-2 positive)[4]. Rates of chemotherapy can vary widely between UK breast units, between 6 and 60% in high risk women[16]. This reflects the fact that most of the randomised trials have upper age cut offs at age 70 or recruit very poorly in this age group, meaning there is little evidence of whether it is effective or not. In addition, there is evidence of an increased risk of significant complications such as neutropenic sepsis in older women [17]. This clearly suggests that guidelines for best practice are required. The primary tool used by oncologists to determine the likely benefit of chemotherapy on a patient level basis is Adjuvant!Online[18], although this has been shown to be inaccurate in older women[19]. The more recently developed PREDICT tool [20] performs better in this age group but has limited functionality for taking co-morbidity and frailty into account.

This cluster randomised trial will evaluate the implementation of two (“complex”) decision support interventions (DESI) designed to be used by both clinicians and patients to assist in the decision making about treatment for early breast cancer in older women.

### **The Bridging the Age Gap Study**

The Bridging the Age Gap study[21] is a NIHR funded programme of research (2012-18RP-PG-1209-10071) examining breast cancer management in older women with the ultimate aim of improving outcomes by providing high quality evidence to support treatment decision making in this age group.

The study protocol reported here focuses exclusively on the cluster randomised trial part of the wider Bridging the Age Gap Study [21]. The study group has developed two patient facing decision support interventions (DESI) based on a systematic evidence summary, expert reference group consultation, patient interviews [22-24] and questionnaires



1  
2  
3 about informational needs and preferences and extensive user- and field-testing with both  
4  
5 healthy older women and older women who had faced the decision relating to the choice of  
6  
7 surgery/AET or PET in frailer women with ER positive breast cancer, and the decision  
8  
9 regarding use of adjuvant chemotherapy in fitter women with high risk cancers. Each DESI  
10  
11 includes a clinician facing clinical management algorithm and two patient facing decision  
12  
13 aids (PtDAs). The clinician facing management algorithms derive from detailed cancer  
14  
15 registry outcome data linked to treatment related morbidity and patient and cancer  
16  
17 characteristics from the UK cancer registry (2002-2010) for two UK regions (Northern and  
18  
19 Yorkshire and East Midlands) which are representative of the UK population as a whole in  
20  
21 terms of demography, population structure and deprivation. This is a large diverse area,  
22  
23 representing 23% of the UK population [25]. These online algorithms allow patient age, co-  
24  
25 morbidities, frailty and cancer characteristics to be considered by a clinician in predicting  
26  
27 survival and cancer outcomes and to help inform breast cancer management decisions for  
28  
29 older women [25]. The PtDAs are in the form of a booklet and a (brief) option grid for the  
30  
31 clinical decision in question [26,27].  
32  
33  
34  
35  
36

37 The trial will evaluate these tools in a cluster randomised trial across 53 UK breast units  
38  
39 according to the study schematic (Figure 1).  
40  
41

42 The aims of this trial is to evaluate if, how and to what extent, the use of the DESIs  
43  
44 embedded as 'standard of care' within intervention-arm sites, improves QoL, decision quality  
45  
46 (integrating knowledge, attitudes and decision made), coping, illness representations and  
47  
48 reduces decision regret, thus indicating improved informed decision making of older women  
49  
50 about treatment options for their breast cancer.  
51  
52

53  
54 To our knowledge this is the first randomised controlled trial to have been undertaken to  
55  
56 explore this issue.  
57  
58  
59  
60

## Objectives

The objectives are to:

1. To assess the effectiveness of the implementation of DESIs [26][27] in clinical practice in terms of improving patient QoL, decision quality (integrating knowledge, attitudes and decision made), coping, illness representations and reducing decision regret, thus indicating improved informed decision making.
2. To determine if, how, or to what extent, the clinical outcomes management algorithm impacts on clinical decision making among clinicians (change in PET/surgery rates and chemotherapy rates).
3. To determine whether the DESIs are effective in improving short, medium and long term cancer outcomes in this age group of women, (treatment morbidity and overall and disease specific survival).
4. To assess the utility and uptake of the DESIs from the perspective of both clinicians and patients by undertaking a formal process evaluation.

## Hypotheses

1. Use of the DESIs will improve the quality of life in older women with operable breast cancer and ultimately improve cancer outcomes.

2. Older women faced with a choice of treatment decisions for their breast cancer will report an improved decision quality and shared decision-making experience and less decision regret using DESIs compared to older women who receive usual clinical decision making support.
3. Use of evidence based DESIs will improve short and longer term outcomes by improving treatment personalisation to a woman's health, fitness and cancer characteristics and by improving the quality of decision making, reduce the heterogeneity of practice across the UK.
4. Women in the intervention sites will express more positive illness representations (e.g. increased personal control, positive emotional consequences, less overall threat) and increased use of engagement coping strategies compared to women from the control sites.

## METHOD

### Study design and setting

This protocol follows the CONSORT statement guidelines for cluster trials [28].

This study is a multi-centre, parallel group, pragmatic cluster randomised controlled trial (2015-18) [29]. It is nested within a larger ongoing Bridging the Age Gap Cohort Study (2012-18) [21] (Figure 1) which is currently recruiting from 53 breast units within in the UK (observational cohort study of current UK management of older women with early breast cancer).

### The RCT study

1  
2  
3 The intervention comprises implementation of a package of two DESIs for the PET versus  
4 surgery/AET, or chemotherapy versus no chemotherapy decisions. Each DESI includes an  
5 online algorithm for treatment outcomes, and two patient decision aids (PtDAs)– a booklet  
6 and a brief option grid [26-27]. Each DESI is a complex intervention, including training for  
7 the clinician (breast surgeon, medical oncologist, breast care nurses) on the use of the  
8 algorithm (surgeons and medical oncologists only) or PtDAs, and the clinician and patient  
9 decide which, if any, of these elements they wish to use to assist the decision making process.  
10 The intention being for the intervention to be used as part of everyday clinical  
11 practice/pathway within the intervention sites.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Each online algorithm includes functionality to adjust outcome prediction according to  
25 patient age, co-morbidity, frailty, tumour stage and ER status and which gives outputs of 2  
26 and 5 year overall and breast cancer specific survival. The algorithms were developed in the  
27 earlier phase of the Age Gap Study [25] and were designed to guide clinicians and their  
28 patients in the treatment of:  
29  
30  
31  
32  
33  
34  
35

36 (1) frailer older women with ER positive breast cancer to optimise treatment with either PET  
37 or surgery/AET,  
38  
39

40 or  
41  
42

43  
44 (2) fitter older women who have already had primary surgery and been found to have high  
45 risk cancer characteristics (e.g. ER negative, Her 2 positive or node positive breast cancer) to  
46 optimise treatment with either adjuvant chemotherapy or no adjuvant chemotherapy (note the  
47 term chemotherapy includes chemotherapy +/- trastuzumab if appropriate).  
48  
49  
50  
51  
52  
53

54 The algorithm is based on a computer model of predicted outcomes and variance caused by  
55 patient and disease parameters. Unlike existing web based algorithms for cancer treatment  
56  
57  
58  
59  
60

1  
2  
3 (Adjuvant! OnLine [19] or PREDICT[20]) which do not have the facility to specify frailty or  
4  
5 comorbidity in detail (or at all), the Age Gap algorithm permits these factors to be taken into  
6  
7 account. The Age Gap tool has been optimised for accuracy in this age group and has been  
8  
9 based on analysis of data from over 20 000 UK women over the age of 70 derived from  
10  
11 cancer registry data. The algorithm has been built into educational materials (including several on  
12  
13 line presentations, data sources, FAQs and an animated educational video). The online  
14  
15 algorithm is designed to be used by clinicians to guide treatment decision making and its  
16  
17 outputs can be printed off in a patient facing format that could be used in personalised patient  
18  
19 counselling. The report provides specific survival estimates for each treatment option for an  
20  
21 individual woman based on her personal and cancer characteristics. This works in much the  
22  
23 same way as the print outs from Adjuvant!Online[19] or PREDICT[20] but in this case  
24  
25 developed for the PET versus surgery/AET decision and with more detailed data entry  
26  
27 relating to the woman's age and fitness level.  
28  
29  
30

31  
32 Two PtDAs (PET versus surgery/AET[26] and chemotherapy versus no chemotherapy [27])  
33  
34 have been developed during the earlier phase of the study [22-24]. The PtDAs comprise of an  
35  
36 option grid [30] and a booklet for each decision. The option grid is a one page evidence-  
37  
38 based summary of the treatment options alongside patients' frequently asked questions,  
39  
40 helping patients to differentiate the key features, risks and benefits of treatment options in  
41  
42 relation to their personal values and preferences. The option grid has been designed to be  
43  
44 sufficiently brief for use in clinical encounters and accessible enough to support a better  
45  
46 dialogue between patients and their clinical team [30]. The booklet provides information  
47  
48 about both options including diagrams, side effects and potential risks and benefits. It also  
49  
50 includes a section to guide deliberation and encourage the patient to clarify their preferences  
51  
52 based around identifying "what is most important to them" [16].  
53  
54  
55  
56  
57  
58  
59  
60

## Eligibility criteria

### Inclusion criteria

- (1) Female
- (2) Aged over 70 years of age at the time of diagnosis of cancer
- (3) Primary operable (TNM categories V7: T1, T2, T3, N0, N1, M0), ER positive invasive breast cancer (core biopsy or diagnostic incision biopsy)
- (4) Ability to give informed consent and to read English

### Exclusion criteria

- (1) Disease unsuitable for surgery e.g. inoperable, locally recurrent or metastatic disease.
- (2) Previous invasive breast cancer within the last 5 years.
- (3) Non-English speakers

## Data Collection and Outcomes.

### Primary outcome measure

The primary outcome measure for the RCT is global health status/QoL score (questions 29+30 only of The European Organization for Research and Treatment of Cancer QLQ-C30 Reference Manual) (EORTC QLQ-C30) [31]. This primary end point was stipulated by the funder of the study with the justification being that the EORTC QLQ-C30 is internationally recognised and well validated QoL measure (as opposed to our original primary endpoint of decision quality). This was measured at 6 weeks and 6 months post diagnosis/consent.

1  
2  
3 An independent data monitoring committee (DMC) comprising of 3 experienced academic  
4 clinicians oversees the study and monitors trial conduct and safety and potential harm and has  
5 access to all study data. The role being to provide recommendations for trial changes (or  
6 closure). Data collection is being undertaken by trained clinical staff within each of the  
7 participating sites. The study data manager and study monitor also undertake regular site  
8 visits to outline the study protocol, ensure protocol adherence and monitor data collection and  
9 completeness. Data collection for the study includes detailed information about the patient  
10 and their cancer at the time of diagnosis: age, comorbidity (Charlson co-morbidity index [32],  
11 frailty- The Barthel Index (ADL) [33] and instrumental activities of daily livingscores (IADL  
12 [34]), cognitive status (Mini-mental state examination-MMSE) [35], baseline QoL (EORTC  
13 QLQ C30 [31], EORTC breast cancer-specific QoL questionnaire (QLQ-BR23) [36],  
14 EORTC QoL questionnaire module for older people with cancer(QLQ-ELD14) [37],  
15 EuroQol Group EQ-5D[38]), tumour stage, grade and receptor status. Treatment details are  
16 recorded including the type of surgery to the breast and axilla, use of adjuvant therapies  
17 (chemotherapy, radiotherapy, trastuzumab and hormonal therapies), including doses and  
18 adverse effects recorded using the Common Terminology Criteria for Adverse Events  
19 grading system. Follow up is at baseline, 6 weeks, 6, 12, 18 and 24 months after  
20 diagnosis/consent. Cancer outcomes, QoL and adverse events are recorded at each visit and  
21 in the longer term, women are asked to sign a consent form to permit the trial to collect their  
22 Cancer Registry data which will be collected 5 and 10 years following diagnosis and consent  
23 to the study. These data will permit us to look at whether using the DESIs alters patterns of  
24 treatment decision making between control and intervention sites and whether these impact  
25 on long term outcomes. As such this is a uniquely detailed evaluation of such DESIs.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54  
55 In addition, specific questionnaires relating to patient choice and decision making will be  
56 administered. These will apply to all women offered a choice of either PET and surgery/AET  
57  
58  
59  
60

1  
2  
3 or chemotherapy versus no chemotherapy and are administered in relation to the time of their  
4  
5 treatment choice. Secondary outcomes measures here include decision regret (Decision  
6  
7 Regret Scale [39], shared decision making (CollaboRATE [40]), patient anxiety (Spielberger  
8  
9 short-form State scale of the State-Trait Anxiety Inventory[41], knowledge and preference  
10  
11 (knowledge, readiness to decide and preference measure[42-43]), illness perceptions (Brief  
12  
13 Illness Perceptions Questionnaire [44]) and Coping(brief COPE)[45]). Original data collected  
14  
15 are entered and kept on file within each of the study sites. This data is entered electronically  
16  
17 and stored securely onto password protected databases within local databases and the main  
18  
19 trial office. All records that contain names or other personal identifiers, such as locator forms  
20  
21 and informed consent forms, are stored separately from study records identified by code  
22  
23 number. Only the study steering and DMC have access to the full trial dataset Errors,  
24  
25 discrepancies or missing data are captured by the computer programme and the study data  
26  
27 manager checks and subsequently follows this up with participating sites.  
28  
29  
30  
31

32  
33 The timescales for each of these are shown in Table 1.  
34

35 Table 1. Data items relating to patient-based outcomes and cancer characteristics.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1: Questionnaire Schedule**

Standard Age Gap Questionnaires	Baseline	6 weeks	6mths	12mths	18/24 mths	Long-term
IADL	*					
ADL	*					
MMSE	*					
ECOG perf. status	*					
Subjective Global Assessment	*					
Co-morbidity	*					
EQ5D	*	*	*	*	*	
QoL (EORTC-QLQ C30; QLQ-BR23 and (QLQ-ELD14)	*	*	*	*	*	
Decision quality	*	*				
RECIST if PET	*	*	*	*	*	
Registry data access						*
Tissue Access	*					*
Tumour details	*					
Treatment details	*	*	*	*	*	
Adverse events	*	*	*	*	*	
<b>New for DESI study</b> (if offered choice of either PET or surgery/AET, or chemotherapy/no chemotherapy)	Baseline (after consent for PET or surgery (AET or after consultation for chemo/no chemo, as applicable)	6 weeks after relevant treatment choice	6 months after relevant treatment choice			
Spielberger Anxiety		*	*			
Collaborate	*					
Decision Regret		*	*			
Knowledge readiness to decide and preference measures	*					
Brief IPQ		*	*			
Brief COPE		*	*			
<b>Process evaluation</b> (if taking part in process evaluation)						
Process evaluation questionnaire		*				

### Sample size calculation

The primary endpoint will be the global health status/QoL scale (questions 29 and 30 of the EORTC-QLQ-C30)[31] at 6 months post baseline. Assuming a SD of 21 points for the global health status/QoL scale and a mean difference of 7 or more points on the global health status/QoL scale between the groups is of clinical/practical importance (a “small” standardised effect size of 0.33). With no allowance for clustering; for the PET versus surgery DESI comparison with 190 eligible women per group we will have a 90% power of detecting this difference or more as statistically significant between the groups at the 5% two-sided level. If we assume an intra-class correlation of 0.03 then allowing for the clustered RCT design we will need to recruit 10 women, eligible for using the decision aids, per cluster (i.e. 50 clusters x 10 women), 500 in total (this assumes a design effect of 1.3). With a 20% loss to follow-up by 6 months we need to recruit 13 women per cluster (50 clusters x 13 women) or 650 in total (325 per group).

### Randomisation

Randomisation is at breast unit level, stratified by high and low PET and chemotherapy rates. It was therefore not possible to blind the investigators or the study sites to the allocation of participants. Data for this stratification have been derived from the wider cohort study which has collected data on treatment rates for both PET versus surgery/AET and chemotherapy versus no chemotherapy.

**Control arm.** Usual standard practice for older women (>70 years) diagnosed with breast cancer with no change to normal treatment decision making practice.

1  
2  
3 **Intervention arm.** Usual standard practice for older women (>70 years) diagnosed with  
4 breast cancer plus optional clinician and patient access to the package of DESIs which will  
5 have been made available to these units to adopt as their standard of care.  
6  
7  
8

9  
10  
11 In the run in to the trial period (June–Dec 2015), clinical teams (clinicians, research and  
12 breast nurses) from the participating sites attended a training event to enhance concordance  
13 with the study protocol (control group) and provide additional training on shared decision  
14 making and the use of the DESIs (intervention group). This comprised of a 2 hour practical  
15 workshop which consisted of presentations, demonstrations and discussion based on the  
16 MAGIC programme [46].  
17  
18  
19  
20  
21  
22  
23

## 24 25 **Recruitment**

26  
27  
28  
29  
30 Potentially eligible women are identified by clinicians (breast surgeons, medical oncologists  
31 and specialist breast nurses) and research nursing staff within multi disciplinary teams of the  
32 study sites. Study packs are being given to eligible patients either following their clinical  
33 consultation where either PET or surgery/AET options or chemotherapy versus no  
34 chemotherapy options are discussed. Monthly study newsletters are sent to all participating  
35 sites to provide feedback to staff in order to maintain interest and recruitment to the study.  
36  
37 Any modifications to the original study protocol will be discussed with the DMEC and  
38 approvals sought from the funder and the ethics committee. Recruitment for the trial has  
39 now commenced and 750 women have been recruited over the 53 participating sites.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 51 **Data analysis**

52  
53  
54 The statistical analyses will be performed on an intention-to-treat basis comparing the DESI  
55 and control groups. All statistical exploratory tests will be two-tailed with  $p=0.05$ . Baseline  
56  
57  
58  
59  
60

1  
2  
3 demographic (e.g. age), physical measurements, and health-related QoL data will be assessed  
4  
5 for comparability between the treatment groups. A marginal Generalised Linear Model  
6  
7 (GLM), with coefficients estimated using generalised estimating equations (GEE) with robust  
8  
9 standard errors and an exchangeable auto correlation matrix in STATA will be used to  
10  
11 analyse the outcomes and allow for the clustered nature of the data. The exchangeable  
12  
13 correlation structure corresponds to an equal correlation model, meaning that the correlations  
14  
15 of the outcomes with a cluster, i.e. breast centres, are the same. For continuous outcomes,  
16  
17 such as mean global health status/QoL score (questions 29+30 of EORTC QLQ-C30 [31]) at  
18  
19 6 months post-diagnosis/consent intervention, knowledge score and preference for treatment  
20  
21 score, an identity link with a Normal distribution for the outcome will be used. Estimates for  
22  
23 the treatment group coefficient from this regression model will be reported along with their  
24  
25 associated 95% confidence interval. In the event of differences between the intervention and  
26  
27 control groups with respect to baseline demographic, physical, and health-related QoL  
28  
29 measurements, then these covariates will be used in the GLM to adjust the treatment effect  
30  
31 for these variables. The adjusted regression coefficient estimate for the treatment group  
32  
33 parameter along with its 95% confidence interval (CI) will then be reported.  
34  
35  
36  
37  
38

39 For the other secondary outcomes, at 6 weeks and 6 months, such as the other dimensions of  
40  
41 the EORTC QLQ C30 [31], the EORTC QLQ-BR23 [36] and EORTC QLQ-ELD14 [37] the  
42  
43 mean QoL dimension scores will be compared between the intervention and control groups,  
44  
45 using similar models.  
46  
47

48  
49 A series of exploratory sub group analyses using a marginal GLM with coefficients estimated  
50  
51 using GEE with robust standard errors and an exchangeable auto correlation matrix, with the  
52  
53 primary outcome the mean Global health status/QoL score (questions 29+30 of EORTC  
54  
55 QLQ-C30 [31]) at 6-month post-diagnosis/consent randomisation as the response will be  
56  
57 carried out. An interaction statistical test between the randomised intervention group and  
58  
59  
60

1  
2  
3 subgroup to directly examine the strength of evidence for the treatment difference between  
4  
5 the treatment groups (Intervention versus Control) varying between subgroups will be  
6  
7 undertaken. Age subgroup (75-79, 80-84, 85-89 and 90+ years) and co-morbidity levels  
8  
9 (based on the modified Charlson co-morbidity score [32]) will be the only a priori defined  
10  
11 sub groups to be considered for interaction test. Sub group analysis will be performed  
12  
13 regardless of the statistical significance on the overall intervention effect (intervention versus  
14  
15 control).

#### 16 17 18 19 Missing primary outcome data

20  
21  
22 A sensitivity analysis using a variety of imputation methods, to impute any missing primary  
23  
24 outcome data (6-month EORTC QLQ-C30 [31] global health status/QoL score) will be  
25  
26 performed. The imputation methods will include last observation carried forward, regression  
27  
28 and multiple imputation. The estimates of the treatment effect and its associated confidence  
29  
30 interval, from the various imputation methods, will be graphically displayed alongside the  
31  
32 results for the observed data.  
33  
34  
35

#### 36 37 **Process Evaluation**

38  
39  
40 Running alongside the main study, a detailed mixed methods process evaluation is being  
41  
42 undertaken at 16 sites to assess the implementation of the DESIs(fidelity to the trial protocol)  
43  
44 to consider the DESIs' usefulness and acceptability and examine the facilitators and barriers  
45  
46 to embedding them into everyday clinical practice. A random selection of breast units was  
47  
48 made stratified by trial arm and recruitment rate to the cohort study (high/low  
49  
50 PET/surgery/chemo rates).  
51  
52

53  
54 In summary, the Age Gap study [21] aims to improving outcomes of older women diagnosed  
55  
56 with breast cancer by providing high quality evidence to support treatment decision making  
57  
58  
59  
60

1  
2  
3 in this age group. The two evidence based DESIs each include a clinical management  
4 algorithm and two patient decision aids (PtDAs) in the form of a booklet and a (brief) option  
5 grid for the clinical decision in question. These online algorithms will allow patient age, co-  
6 morbidity, frailty and cancer characteristics to be considered by a clinician in predicting  
7 survival and cancer outcomes and to help inform breast cancer management decisions for  
8 older women.  
9  
10  
11  
12  
13  
14  
15

### 16 **Acknowledgments**

17  
18  
19  
20 The authors are grateful to all participating sites, and specifically site principal investigators  
21 (PI) who have or who are currently contributing to the RCT  
22  
23  
24

25  
26 **Competing interests:** None declared  
27  
28

29 **Funding:** This work is supported by National Institute of Health Research Programme Grant  
30 [grant number RP-PG-1209-10071]  
31  
32  
33

34 **Contributors** LW, KC and MR were overall project leads. Decision aid development and  
35 testing KL, MB, KC, LW, MR, AE, KB, JG, DR, FA, HH. Trial management: LW, CM, TC,  
36 KP. On line tool development: LW, SW, PR, AN, CM, MB, JM. Statistical advice: SW, OB.  
37 Trial management group: LW, MR, KC, TR, KLC, AR, etc. Chemotherapy advisors: AR,  
38 RL, HH. All authors have contributed to reading and approved the final manuscript.  
39  
40  
41  
42  
43  
44

45 **Provenance and peer review:** Not commissioned; externally peer reviewed  
46  
47  
48

49 **Open access:** This is an Open Access article distributed in accordance with the Creative  
50 Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to  
51 distribute, remix, adapt, build upon this work non-commercially, and license their derivative  
52 works on different terms, provided the original work is properly cited and the use is non-  
53 commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Cancer Research UK breast cancer incidence [accessed 1/11/2016] Available from <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer>
2. Office for National Statistics. New cases of cancer diagnosed in England, 2014: selected sites by age group and sex. Office for National Statistics 2010[accessed 1/11/2016] Available from <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregistrationssummarytables/previousReleases>
3. Morgan J, Richards P, Ward S et al (2015) Case mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer. *British Journal of Surgery*. 102 (9), 1056-1063.
4. Ring A, Harder H, Langridge C et al. Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. *Ann Oncol*. 2013;24(5):1211-9.
5. BCCOM. Breast Cancer Clinical Outcome Measures (BCCOM) Project. Birmingham, UK; 2007
6. Chakrabarti J, Kenny FS, Syed BM, et al. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer- final results at 20-year follow-up. *Crit Rev OncolHematol* 2011;78:260-264.
7. NICE. Early and locally advanced breast cancer: full guideline. Cardiff: National Collaborating Centre for Cancer; 2009.
8. Biganzoli L, Wildiers H, Oakman C. et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology

- 1  
2  
3 (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). *Lancet Oncol*  
4  
5 2012;13:e148-e160.  
6  
7  
8 9. Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older  
9  
10 women with operable breast cancer - a comparison of randomised controlled trial and  
11  
12 cohort study findings. *Eur J Surg Oncol*. 2014;40(6):676-84.  
13  
14  
15 10. Glas de, NA, Jonker JM, Bastiaannet E, et al. Impact of omission of surgery on  
16  
17 survival of older patients with breast cancer. *Br J Surg*. 2014;101(11):1397-404.  
18  
19  
20 11. Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone  
21  
22 for older women with operable breast cancer: cochrane review. *Br J Cancer*.  
23  
24 2007;96(7):1025-9.  
25  
26 12. Morgan J, Wyld L, Collins K, et al. Surgery versus primary endocrine therapy for  
27  
28 operable primary breast cancer in elderlywomen (70 years plus). *Cochrane Db Syst*  
29  
30 *Rev* 2014;5:CD004272.  
31  
32  
33 13. Audisio RA, Wyld L. No standard is set for older women with breast cancer. *Eur J*  
34  
35 *SurgOncol* 2015 May; 41 (5): 607  
36  
37  
38 14. Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older  
39  
40 women with operable breast cancer - a comparison of randomised controlled trial and  
41  
42 cohort study findings. *Eur J SurgOncol*. 2014;40(6):676-84.  
43  
44  
45 15. Hille U, Soergel P, Länger F, et al. Aromatase inhibitorsas solely treatment in  
46  
47 postmenopausal breast cancer patients. *Breast J* 2012;18(2):145–50.  
48  
49  
50 16. Elwyn G, Frosch D, Thomson R et al. Shared decision making: a model for clinical  
51  
52 practice. *J Gen Intern Med* 2012 Oct; 27 (10): 1361-7.  
53  
54  
55 17. NICE Clinical guideline. Neutropenic sepsis: prevention and management in people  
56  
57 with cancer. CG151]Published date: September 2012  
58  
59  
60



- 1  
2  
3 18. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making  
4 decisions about adjuvant therapy for women with early breast cancer. *J Clin Oncol.*  
5 2001;19(4):980-91.  
6  
7  
8  
9  
10 19. deGlas NA, van de Water W, Engelhardt EG, et al. Validity of Adjuvant! Online  
11 program in older patients with breast cancer: a population-based study. *Lancet Oncol.*  
12 2014;15(7):722-9.  
13  
14  
15  
16 20. Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic  
17 model that predicts survival following surgery for invasive breast cancer. *Breast*  
18 *Cancer Res.* 2010; 12(1): R1. Published online 2010 January 6. doi: 10.1186/bcr2464.  
19  
20  
21  
22  
23  
24  
25  
26 21. Wyld L, Reed MWR, Collins K et al .Bridging the Age Gap in Breast Cancer:  
27 Improving outcomes for older women NIHR Programme grant 2012-17RP-PG-1209-  
28 10071[Accessed 18/11/ 2016] Available at [http://www.nihr.ac.uk/funding/funded-](http://www.nihr.ac.uk/funding/funded-research/funded-research.htm?postid=2237)  
29  
30  
31  
32  
33  
34 22. Lifford KJ, Witt J, Burton M, et al. Understanding older women's decision making  
35 and coping in the context of breast cancer treatment. *BMC Medical Informatics &*  
36  
37  
38  
39  
40  
41 23. Burton M, Collins K, Caldon LJM et al. Information Needs of Older Women Faced  
42 With a Choice of Primary Endocrine Therapy or Surgery for Early Stage Breast  
43  
44  
45  
46  
47  
48 24. Burton M, Collins K, Lifford K et al. The information and decision support needs of  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 25. Richards P, Ward S, Morgan J, et al. The use of surgery in the treatment of ER+ early  
4 stage breast cancer in England: variation by time, age and patient characteristics.  
5 European Journal of Surgical Oncology. 2016; 42(4) 489-96.  
6  
7  
8  
9  
10 26. Deciding about your breast cancer treatment: surgery and hormone-blocking pills or  
11 hormone-blocking pills only. Cardiff University, The University of Sheffield,  
12 Sheffield Hallam University developed as part of the Bridging the Age Gap Study  
13 (RP-PG-1209-10071) August 2015.  
14  
15  
16  
17  
18 27. Deciding about your breast cancer treatment: chemotherapy or no chemotherapy. The  
19 University of Sheffield ,Brighton and Sussex Medical School, Sheffield Hallam  
20 University and Cardiff Universityas part of the Bridging the Age Gap Study (RP-  
21 PG-1209-10071) January 2016.  
22  
23  
24  
25  
26  
27 28. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated  
28 guidelines for reporting parallel group randomized trials. Ann Intern Med.  
29 2010;152(11):726-32.  
30  
31  
32  
33  
34 29. Wyld L, Reed MWR, Collins K on behalf of the Age Gap study. A multi-centre, parallel  
35 group, pragmatic cluster randomised controlled trial NIHR Programme grant RP-PG-1209-  
36 1007.EUDRACT No:2015-004220-61  
37  
38  
39  
40  
41  
42 30. Marrin k, Brain K, Durand MA, Edwards A et al. . Fast and frugal tools for shared  
43 decision making: How to develop option grids.European Journal for Person Centered  
44 Health Care. 2013;1(1):240-5.  
45  
46  
47  
48 31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for  
49 Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in  
50 international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying  
4 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic*  
5  
6  
7 Dis. 1987;40(5):373-83.  
8  
9  
10 33. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J.*  
11  
12 1965;14:61-5.  
13  
14 34. Lawton MP, Brody EM. Assessment of older people: self-maintaining and  
15  
16 instrumental activities of daily living. *Gerontologist.* 1969;9(3):179-86.  
17  
18 35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for  
19  
20 grading the cognitive state of patients for the clinician. *J Psychiatr Res.*  
21  
22 1975;12(3):189-98.  
23  
24 36. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for  
25  
26 Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire  
27  
28 module: first results from a three-country field study. *J Clin Oncol.*  
29  
30 1996;14(10):2756-68.  
31  
32 37. Johnson C, Fitzsimmons D, Gilbert J et al. Development of the European  
33  
34 Organisation for Research and Treatment of Cancer quality of life questionnaire  
35  
36 module for older people with cancer: The EORTC QLQ-ELD14. *Eur J Cancer.*  
37  
38 2010;46(12):2242-52.  
39  
40 41  
42 43 38. EuroQol Group EuroQol—A new facility for the measurement of health-related  
44  
45 quality of life  
46  
47 48 39. Health Policy, 16 (1990), pp. 199–208. Brehaut JC, O'Connor AM, Wood TJ, Hack  
49  
50 TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. *Med Decis*  
51  
52 Making. 2003;23(4):281-92.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 40. Barr PJ, Thompson R, Walsh T, et al. The psychometric properties of CollaboRATE:  
4 a fast and frugal patient-reported measure of the shared decision-making process. J  
5 Med Internet Res. 2014;16(1):e2.  
6  
7  
8  
9  
10 41. Marteau TM, Bekker H. The development of a six-item short-form of the state scale  
11 of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992;31 (  
12 Pt 3):301-6.  
13  
14  
15  
16 42. Sepucha K, Ozanne E, Silvia K, et al. An approach to measuring the quality of breast  
17 cancer decisions. Patient Educ Couns. 2007;65(2):261-9.  
18  
19  
20  
21 43. Sepucha KR, Belkora JK, Chang Y, et al. Measuring decision quality: psychometric  
22 evaluation of a new instrument for breast cancer surgery. BMC Med Inform Decis  
23 Mak. 2012;12:51.  
24  
25  
26  
27 44. Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J  
28 Psychosom Res. 2006;60(6):631-7.  
29  
30  
31  
32 45. Carver CS. You want to measure coping but your protocol's too long: Consider the  
33 Brief COPE. International Journal of Behavioral Medicine. 1997; 4, 92-100. .  
34  
35  
36 46. Lloyd A & Joseph-Williams N. Case Study: Different outcomes from different  
37 approaches – Experience from the Cardiff MAGIC Programme, UK. In Elwyn G,  
38 Edwards A, Thompson R (eds.) Shared Decision Making in Health Care. 3<sup>rd</sup> edition.  
39 2016. Oxford: Oxford University Press.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: Overview of the Cluster randomised Controlled Trial

335x182mm (300 x 300 DPI)

review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	4
	2b	All items from the World Health Organization Trial Registration Data Set	Within main protocol but N/A for journal
Protocol version	3	Date and version identifier	Within main protocol but N/A for journal
Funding	4	Sources and types of financial, material, and other support	23
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	23
	5b	Name and contact information for the trial sponsor	4
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	4

1			
2			
3		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
4			Within main protocol but N/A for journal
5			
6			
7			
8			
9			
10			
11	<b>Introduction</b>		
12			
13	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
14			6-8
15		6b	Explanation for choice of comparators
16			18,19
17	Objectives	7	Specific objectives or hypotheses
18			10-11
19	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
20			11
21			
22			
23			
24	<b>Methods: Participants, interventions, and outcomes</b>		
25			
26	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
27			11
28	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
29			14
30	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
31			12-13
32		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
33			15
34		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
35			19
36		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
37			N/A
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

1				
2				
3	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	15-17
4				
5				
6				
7				
8	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	17
9				
10				
11	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	18
12				
13				
14	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	19
15				
16				

### 17 **Methods: Assignment of interventions (for controlled trials)**

#### 18 Allocation:

19				
20				
21	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	18
22				
23				
24				
25				
26	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	N/A 18
27				
28				
29				
30	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	18
31				
32				
33				
34	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A 18
35				
36				
37		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
38				
39				

### 40 **Methods: Data collection, management, and analysis**



1				
2				
3	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	14-16
4	methods		processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of	
5			study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	
6			Reference to where data collection forms can be found, if not in the protocol	
7				
8		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	17
9			collected for participants who discontinue or deviate from intervention protocols	
10				
11	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality	16
12			(eg, double data entry; range checks for data values). Reference to where details of data management	
13			procedures can be found, if not in the protocol	
14				
15	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the	19-21
16			statistical analysis plan can be found, if not in the protocol	
17				
18		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	21
19				
20		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any	21
21			statistical methods to handle missing data (eg, multiple imputation)	
22				
23				
24	<b>Methods: Monitoring</b>			
25				
26	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of	15
27			whether it is independent from the sponsor and competing interests; and reference to where further details	
28			about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not	
29			needed	
30				
31		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim	17
32			results and make the final decision to terminate the trial	
33				
34				
35	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse	15
36			events and other unintended effects of trial interventions or trial conduct	
37				
38	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent	15,17
39			from investigators and the sponsor	
40				
41				
42	<b>Ethics and dissemination</b>			
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	22
4				
5				
6	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	15
7				
8				
9				
10	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	19
11				
12				
13		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
14				
15				
16	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	16
17				
18				
19	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	23
20				
21				
22	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	15
23				
24				
25	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
26				
27				
28				
29	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	22
30				
31				
32				
33		31b	Authorship eligibility guidelines and any intended use of professional writers	23
34				
35		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	23
36				
37	<b>Appendices</b>			
38				
39	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Provided in main protocol not journal
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1  
2  
3 Biological 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular N/A  
4 specimens analysis in the current trial and for future use in ancillary studies, if applicable  
5

---

6 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
7 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
8 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only